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Interferons (IFN) are cytokines that regulate anti tumour, immune 
and anti viral responses in vertebrates. Retinoic acid (RA) is a metabolite 
of vitamin A that has profound effects on metabolism, cell growth and 
differentiation. The combinatorial therapeutic effect of IFN/RA has been 
shown to be more potent in fighting cancer cells than that of either drug 
alone. GRIM-19 is a protein that was identified to be one of the 
downstream players of the IFN/RA induced cell death pathway. 
Subsequent studies showed that it is a subunit of mitochondrial complex 
I. However, little is known about the role of GRIM-19 in maintaining 
mitochondrial homeostasis and IFN/RA mediated cell death. As 
mitochondria are highly dynamic organelles, in this study, we tried to 
explore the role of GRIM-19 in maintaining the morphology and other 
vital functions of the mitochondria.  
The localization of GRIM-19 was controversial with studies 
reporting that it is present in the cytoplasm and the nucleus apart from 
the mitochondria. Here, I show that GRIM-19 clearly localizes only to the 
mitochondria. The results also show that GRIM-19 over expression or 
knock down (KD) does not affect the morphology or dynamics of 
mitochondria. While studying the role of GRIM-19 in mitochondrial 
functions, I observed that ROS increases upon GRIM-19 KD. Apart from 
this, I also investigated the characteristics of three GRIM-19 mutants 
 x 
 
which had lost the capacity to inhibit STAT3-induced cellular 
transformation identified from human patient tumour samples. These 
mutants are not able to rescue the increase in ROS production caused by 
the knock down of GRIM-19. Down-regulation of GRIM-19 has been 
reported in several cancers. Research has also shown that cancer cells 
exhibit a higher level of ROS than do normal cells. With these results and 
further studies on the physiological significance of the interaction of 
STAT3 and GRIM-19 with respect to the mitochondria, it would be 
possible to elucidate the mechanism by which absence or mutations of 
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Chapter 1  INTRODUCTION 
1.1 MITOCHONDRIA 
1.1.1 Origin  
Multicellular organisms are composed of variety of tissues which 
are in turn made up of individual functional units called cells. Each cell is 
made up of a myriad of sub cellular organelles. Amongst them, one of the 
most important is the mitochondrion. According to the endosymbiotic 
theory, mitochondria are descendants of ancient bacteria that entered 
into a symbiotic relationship with primitive host cells (Gray et al., 1999). 
They retain several features of their putative bacterial ancestors like the 
double membrane, a proteome similar to that of α-proteobacteria and the 
ability to synthesize ATP through a proton gradient generated across 
their inner membrane. Mitochondrial morphologies vary widely among 
different cell types. Fibroblast mitochondria, for instance, are usually long 
filaments (1 to 10 µm in length with a reasonably constant diameter of 
~700 nm), whereas hepatocyte mitochondria are more uniformly spheres 
or ovoids (Youle and van der Bliek, 2012). The number of mitochondria in 
a cell can also vary widely depending on the organism, tissue, and cell 
type. For example, red blood cells have no mitochondria, whereas liver 
cells can have more than 2000. Since their main role is production of 
energy, they are referred to as the “powerhouse of the cell” and are 
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abundant in cells that have a high energy requirement like neurons and 
cardiomyocytes.  
1.1.2 Structure 
Mitochondria are semi-autonomous organelles that contain their 
own genome and protein synthesis machinery. These are enclosed in a 
double membrane that is made up of phospholipids and proteins. There 
are four main parts to the structure of a mitochondrion, namely the outer 
mitochondrial membrane (OMM), the inter-membrane space (IMS), the 
inner membrane (IMM) and the matrix (Friedman and Nunnari, 2014).   
OMM contains large numbers of integral proteins called porins. 
These porins form channels that allow molecules 5000 Daltons or less in 
molecular weight to freely diffuse from one side of the membrane to the 
other. Proteins larger can enter the mitochondrion if their N-
terminus hosts a signalling sequence that binds to a large multi-
subunit protein called translocase of the outer membrane, which then 
actively moves them across the membrane (Hay et al., 1984).  
IMS also called the peri-mitochondrial space is the space between 
the outer and the inner membranes. Of late, many studies have revealed 
the protein composition of the IMS. One important protein that is 
localized to this compartment is cytochrome c which plays a significant 
role in the apoptotic signalling cascade (Chipuk et al., 2006). It is an 
essential component of the respiratory electron transport chain, and has 
been identified as a potent activator of apoptosis when released into the 
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cytosol. Other potential killers residing within the IMS are proapoptotic 
members of the caspase family : caspase-9, caspase-2 and caspase-3 and a 
flavoprotein known as an apoptosis-inducing factor (AIF) (Alnemri, 
1999). 
 IMM has a high protein to phospholipid ratio and is made up of 
proteins with highly specific functions for the synthesis of ATP. These are 
discussed in detail in the following sub-headings. Unlike the OMM, the 
IMM does not contain porins and is highly impermeable. Most of the ions 
and molecules require special membrane transporters to enter or exit the 
matrix. Proteins are ferried into the matrix via the translocase of the inner 
membrane (TIM) complex or via Oxa1 (Herrmann and Neupert, 2000). In 
addition, there is a membrane potential across the inner membrane, 
generated by the action of the enzymes of the electron transport chain 
(Tupper and Tedeschi, 1969). The IMM is compartmentalized into 
numerous cristae, which help to expand the surface area, enhancing its 
ability to produce ATP. The ratio of the area of the OMM and the IMM is 
variable and mitochondria in cells that have a greater demand for ATP, 
such as muscle cells, contain much more cristae than normal cells. These 
folds are embedded with small round bodies known as F1 particles or 
oxysomes. These invaginations of the IMM can affect overall  
chemiosmotic function (Mannella, 2006). A recent study using 
mathematical modelling has suggested that the optical properties of the 
cristae in filamentous mitochondria may affect the generation and 
propagation of light within the tissue (Thar and Kuhl, 2004).  
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Matrix is the space enclosed by the IMM. It houses about two-
thirds of the total protein in a mitochondrion. The matrix aids in the 
production of ATP with the help of the ATP synthase contained in the 
inner membrane. It contains a highly concentrated mixture of hundreds of 
enzymes, mitochondrial ribosomes, tRNA, apart from several copies of 
the mitochondrial DNA. The major functions of the enzymes include 
oxidation of pyruvate and fatty acids, and the citric acid cycle.  As 
mentioned earlier, mitochondria are semi-autonomous organelles 
meaning that they have the ability to self replicate with the help of their 
exclusive mitochondrial DNA (mt DNA) (Gray, 1989). In addition, they 
also possess the necessary machinery to manufacture their own 
RNAs and proteins.  Research on human mitochondrial DNA sequence 
revealed that it is 16,569 base pairs long, encoding 37 total genes: 
22 tRNA, 2 rRNA, and 13 polypeptide genes (Anderson et al., 1981). The 
13 mitochondrial polypeptides in humans are integrated into the inner 
mitochondrial membrane complexes about which the later sections 
describe in more detail.  
1.1.3 Function 
On the one hand, mitochondria produce metabolic energy in the 
form of ATP; on the other hand, they are involved in the process of 
apoptosis or programmed cell death, and harbour proteins that are 
potentially lethal to vertebrate cells. The following sections aim to give a 




1.1.4 Respiratory chain (or ETC), OXPHOS and the production of ROS 
Most eukaryotic mitochondria produce ATP from products of the 
citric acid cycle, fatty acid oxidation, and amino acid oxidation. On the 
mitochondrial inner membrane, electrons from NADH and succinate go 
through the electron transport chain to oxygen, which is eventually 
reduced to water. The electron transport chain is made up of an 
enzymatic series of electron donors and acceptors. Each electron donor 
shuttles electrons to a more electronegative acceptor, which in turn 
donates these electrons to another acceptor, a process that continues 
down the series until electrons are passed to oxygen, the most 
electronegative and terminal electron acceptor in the chain (Tzagoloff, 
1974). Shuttle of electrons between donor and acceptor releases energy, 
which is used to create a proton gradient across the mitochondrial 
membrane by actively “pumping” protons into the IMS, producing a 
thermodynamic state (Gibb’s free energy) that has the potential to do 
work. The entire phenomenon is called oxidative phosphorylation, since 
ADP is phosphorylated to ATP using the energy of hydrogen oxidation in 
many steps. 
A note worth mention is that a small percentage of electrons do 
not complete the whole sequence and instead directly leak to oxygen, 
resulting in the formation of the free-radical superoxide, a member of the 
highly reactive oxygen molecules (ROS) that contributes to oxidative 
stress and has been implicated in a number of diseases. Four membrane-
bound complexes have been known in mitochondria (Tzagoloff, 1974). 
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Each is an extremely complex trans-membrane structure made up of 
several sub-units and embedded in the inner membrane. Three of them 
are proton pumps. The structures are electrically linked by lipid-soluble 
electron carriers and water-soluble electron carriers. In summary, the 
flow of electrons is as described here. Complex I (NADH coenzyme Q 
reductase) accepts electrons from the Krebs cycle electron carrier NADH, 
and passes them to coenzyme Q (ubiquinone), which also receives 
electrons from complex II (succinate dehydrogenase). UQ transports 
electrons to complex III (cytochrome bc1 complex), which passes them to 
cytochrome c (cyt c). Cyt c then transfers electrons to Complex IV 
(cytochrome c oxidase; labeled IV), which utilizes the electrons and 
hydrogen ions to reduce molecular oxygen to water. 
The efflux of protons from the mitochondrial matrix creates an 
electrochemical gradient (a.k.a proton gradient). This gradient is used by 
the FOF1 ATP synthase complex (sometimes referred to as Complex V of 
the ETC) to make ATP via oxidative phosphorylation. 
1.1.5 Membrane potential and its significance 
The oversimplified view that mitochondria are purely metabolic 
organelles was discarded with the finding that the disruption of the 
mitochondrial trans-membrane potential (Δψm) forms an early and 
irreversible step in the cascade of events that lead to apoptotic cell death 
(Zamzami et al., 1995). 
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The mitochondrial potential (Δψm) provides the charge gradient 
required for mitochondrial Ca2+ sequestration, and regulates reactive 
oxygen species (ROS) production, and thus is also a central regulator of 
cell health (Ly et al., 2003). Under cellular stress, Δψm may be altered by 
dysregulated intracellular ionic charges [e.g., Ca2+ or K+], subsequently 
changing the total force driving protons into the mitochondria and thus 
ATP production. When ionic fluxes exceed the ability of mitochondria to 
buffer these changes, ultimately Δψm along with its components may 
collapse, leading to a failure of ATP production and bioenergetic stress. 
The approximate physiological value of mitochondrial potential is Δψm = 
150 mV  (Perry et al., 2011).  
1.1.6 In apoptosis/programmed cell death 
The apoptotic pathway that involves the mitochondria is activated 
by many triggers, such as growth factor deprivation, glucocorticoids, 
cytotoxic agents and mitogenic oncogenes. These stimuli in some way 
lead to an increase in the permeability of the OMM and promote the 
release of cytochrome c into the cytosol (Alnemri, 1999). 
 One of the first cues that mitochondria participate in the 
regulation of apoptosis stemmed from the observation that in 
Caenorhabditis elegans, CED-9 (the worm orthologue of human B cell 
lymphoma 2 (BCL-2)), a constituent of the core apoptotic machinery, is 
tethered to the mitochondrial outer membrane. Although mitochondria 
were initially thought to operate as mere signalling scaffolds in this 
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framework, it soon became clear that they actively regulate programmed 
cell death in an extensive group of organisms, ranging from lower 
eukaryotes like yeast to humans. In fact, mitochondrial outer membrane 
permeabilization (MOMP) represents a near-universal event that marks 
an irreversible point followed by multiple signal transduction cascades, 
leading to cell death be it through apoptosis or regulated necrosis (Chipuk 
et al., 2006). Thus, it is unambiguous that mitochondria occupy a central 
position in the regulation and execution of cell death. Hence, 
understandably, defects that alter the ability of mitochondria to execute 
MOMP are associated with a variety of human pathologies, including 
infectious diseases, ischaemic conditions, neurodegenerative disorders 
and cancer (Galluzzi et al., 2012; Kroemer et al., 2007; Tait and Green, 
2010). Moreover, it has recently been proved that mitochondria also 
release mitochondrial DNA (mtDNA), metabolic by-products such as 
reactive oxygen species (ROS) and specific nucleus-encoded proteins as 
danger signals to alert the cell of perturbations in mitochondrial 
homeostasis (Krysko et al., 2011). Apart from the aforesaid functions, 
they also contribute to the biosynthesis of pyrimidines, amino acids, 
phospholipids, nucleotides, folate coenzymes, heme, urea, and many other 
metabolites. 
1.1.7 Dynamics 
Mitochondria viewed in live cells reveal that their morphologies are far 
from static. Their shapes change constantly through the combined actions 
of fission, fusion, and motility. Recurrent cycles of fusion and fission result 
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in the intermixing of the mitochondrial population in the cell (Chan, 
2012). Increased fusion or reduced fission causes the formation of 
elongated mitochondrial networks, while increased fission or reduced 
fusion leads to mitochondrial fragmentation. The key molecules in both 
fusion and fission are large GTP-hydrolysing enzymes of the dynamin 
superfamily. Mitochondrial fusion involves two sequential steps: first, the 
outer membranes (OMMs) of two mitochondria fuse followed by the 
fusing of their inner membranes (IMMs). OMM fusion is carried out by 
mitofusin 1 (MFN1) and mitofusion 2 (MFN2), which are dynamin-related 
GTPases located at the OMM. IMM fusion is mediated by the dynamin-
related protein optic atrophy 1 (OPA1) (Refer Figure 1.1).  While cells that 
lack both MFNs have no mitochondrial OMM fusion, cells lacking OPA1 
exhibit OMM fusion events, but the fusion intermediates cannot progress 
to IMM fusion. The opposite process of mitochondrial fission involves the 
recruitment of dynamin-related protein 1 (DRP1) from the cytosol to the 
OMM. Assembly of DRP1 on the mitochondrial surface causes the 
formation of a ring structure at the point of constriction of the 
mitochondria leading to the eventual division of the organelle into two 




1.2 INTERFERON-RETINOIC ACID INDUCED CELL DEATH PATHWAY 
1.2.1 Interferon signalling 
Cytokines are small proteins that play an important role in cell 
signalling. They include chemokines, interferons, interleukins, 
lymphokines, tumour necrosis factors with the exception of hormones 
and growth factors. They are secreted by a broad range of cells, including 
immune cells like macrophages, B lymphocytes, T lymphocytes and mast 
cells, as well as endothelial cells, fibroblasts, and various stromal cells. 
Cytokines protect the host from infectious pathogens (Evan and Vousden, 
2001). 
The interferon (IFN) family of cytokines regulates antiviral, 
antitumor, and immunoregulatory activities (Sen, 2000). IFNs used two 
classes of transcription factors, Janus tyrosine kinases (JAK)-Signal 
Transducing Activator of Transcription (STAT) pathway (Levy and 
Darnell, 2002) and Interferon gene-Regulatory Factors (IRFs) (Fujita et 
Figure 1-1: Fusion and Fission of mitochondrial membranes  
a) Fusion of OMM is mediated by MFN1/2 whereas IMM fusion is mediated by 
OPA1. 
b) Once recruited on to the OMM, Drp1 aids in the fission of mitochondria 
through the formation of a ring structure (Adapted from Mishra et al., 2014) 
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al., 1989) to stimulate the expression of a number of cellular genes, which 
bring about their diverse actions.  IRFs primarily regulate the expression 
of IFN genes and some Interferon stimulated genes (ISGs) while the 
STATs mostly regulate ISGs. However, it was observed that these factors 
cross-regulate each other and form complexes with other factors to 
deliver specific biological responses, based on the elements present in the 
ISG promoter (Ozato et al., 2007). For example, the Interferon-Stimulated 
Response Element (ISRE) binds to a heteromeric transcription factor, 
ISGF3, consisting of IRF9, STAT1 and STAT2, for inducing transcription of 
certain ISGs (Stark et al., 1998). Similarly, the binding of activated STAT1 
dimer to Gamma-Activated Sites (GAS) of some ISGs stimulates gene 
expression in response to IFN-γ (Shuai et al., 1992). Cytokine-induced 
responses driven by STATs are controlled by feedback mechanisms, 
which regulate gene expression.  
Transcription factors as they are, STAT1 and IRFs, their inhibitory 
effects on growth are eventually dependent on the downstream gene 
products induced by them. Among these products, two antiviral enzymes, 
protein kinase R (PKR) and Ribonuclease L (RNaseL) have been found to 
be important in stress-induced and spontaneous apoptosis (Balachandran 
et al., 1998; Zhou et al., 1997). Nevertheless, growth suppressive actions 
of IFNs independent of PKR and RNaseL have also been described 
(Kalvakolanu, 2000; Levy-Strumpf and Kimchi, 1998). The other proteins 
that are regulated by IFNs are pRB, which is a growth suppressor and is 
activated (Resnitzky et al., 1992); c-myc, E2F and cyclin D3 which are pro-
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proliferation genes down regulated in certain lymphoblastoid tumor cell 
lines (Tiefenbrun et al., 1996).  
1.2.2 Interferons and cell cycle regulation 
As mentioned above, IFNs inhibit cell growth by inducing either 
growth arrest or apoptosis. Although growth arrest in some cases leads to 
the activation of apoptosis, these events are clearly regulated by different 
gene products. Of note is the fact that cell death can occur independently 
of growth arrest. IFNs target specific proteins involved in growth arrest 
and cell death responses. Whether one or both of these processes are 
activated in cells is dependent on the cell type (Hertzog and Williams, 
2013). IFNs either alter the activities of proteins that control the cell cycle 
or IFN-induced proteins interact with the cell cycle machinery for 
inducing growth arrest. For instance, IFN-γ activates the expression of 
p21/WAF/Cip-1, a cyclin dependent kinase inhibitor, to cause growth 
arrest in some cell types (Chin et al., 1996). It is important to note that 
induction of p21/WAF/Cip-1 by IFN-γ does not involve p53 (el-Deiry, 
1998), a typical inducer of this inhibitor. STAT1 directly induces the 
p21/WAF/Cip-1 gene. IFNs also inhibit cell growth by downregulating c-
myc expression (Raveh et al., 1996), inactivating the transcription factor 
E2F (Melamed et al., 1993) and inducing/dephosphorylating the 
retinoblastoma tumor suppressor (pRb) in lymphoid tumor cells 
(Resnitzky et al., 1992). In the context of apoptosis, some studies suggest 
that caspases are activated by IFNs. Not surprisingly, IFN-γ induced 
apoptosis requires JAK1 and STAT1, and an induced expression of 
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caspase-1 (Chin et al., 1996). It was found that STAT binding sites are 
present in the promoter of caspase 1. However, the role of caspase-1 in 
apoptosis is less known, since mice lacking this gene exhibit normal 
apoptotic response (Kuida et al., 1995). Interestingly, TNF-α induced 
apoptosis is also found to be defective in STAT1 null cells. 
1.2.3 IFN and cancer 
An important role for IFNs in controlling carcinogenic cell growth 
was highlighted by observations such as an increased occurrence of 
carcinogen-induced tumors in the IFN-γ receptor-/- and STAT1-/- mice, 
and an inability of the immune system to reject the STAT1-null tumors 
(Kaplan et al., 1998). Some IFN-regulated factors such as IRF-1 and IFN- 
consensus sequence binding protein (ICSBP) behave as tumor growth 
suppressors. Mutations in these genes have been reported in the 
development of myeloid leukemias with the deletion of IRF8 gene causing 
a CML-like disease in mice (Holtschke et al., 1996; Willman et al., 1993). 
Also, loss of IRF8/ICSBP expression of occurs in CML patients (Schmidt et 
al., 1998); whereas re-expression of IRF8 suppressed BCR-ABL oncogene-
induced CML-like disease in mouse models (Hao and Ren, 2000).  
Though the effectiveness of IFNs has been proven in the therapy of 
certain leukaemias, they yield poor results in the case of solid tumors 
(Gutterman, 1994). In an effort to overcome this drawback, a number of 
combination therapies have been studied for their enhancement of 
effectiveness. Among these, the combination of IFNs with retinoids was 
found to be most potent against several tumors (Moore et al., 1994). 
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1.2.4  Retinoids signalling 
Retinoids are produced from dietary vitamin A, in particular from 
eggs, milk, butter and fish-liver oils, and the pro-vitamin β-carotene of 
plant source. Once taken up by the intestinal mucosa cells, retinol is 
esterified to retinyl esters subsequently passing into the lymphatic 
system and transported by the blood in chylomycrons, from where they 
are taken up by the liver and stored. After it is mobilized, retinol is 
oxidized to retinal and retinoic acid (RA) by cleavage of retinyl esters 
(Altucci and Gronemeyer, 2001). Gene-ablation experiments 
(Niederreither et al., 1999) show that the production of retinoic acid by 
the retinaldehyde dehydrogenase-2 enzyme is required for mouse 
embryo survival and early morphogenesis. A very small proportion of 
plasma and tissue retinol (0.2–5%) is converted to all trans RA (ATRA), 
the main activator of RA receptors that can drive all functions of vitamin A 
except vision (Love and Gudas, 1994). RA is a crucial regulator of 
embryogenesis, and its production needs to be carefully controlled for 
proper organogenesis. Very little vitamin A leads to severe malformation 
whereas high concentrations of retinoids are teratogenic, strengthening 
the idea that RA may play the role of a morphogen during early 
embryogenesis (Altucci and Gronemeyer, 2001).  
Retinoids employ two structurally similar, but genetically distinct, 
classes of nuclear transcription factors, viz., Retinoic Acid Receptors 
(RARs) and Retinoid X Receptors (RXRs) to drive the expression of genes 
that contain the Retinoic Acid Response Elements (RARE) (Mangelsdorf 
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and Evans, 1995; Nagpal et al., 1992). Targeted gene disruption 
experiments have shown that nearly all the congenital malformations that 
are caused by vitamin A deficiency are due to the absence of RAR or RXR 
functions (Kastner et al., 1995). The RAR: RXR heterodimers bind to RARE 
constitutively, whose transcriptional activity is held in check by several 
co-repressor molecules. Binding of RA to the RAR induces a 
conformational change that allows the recruitment of nuclear receptor co-
activators, which promote transcription. A number of isotypes and 
subtypes of RARs and RXRs (α, β and γ) participate in retinoid-induced 
transcription in a gene- and cell specific manner. Most RAR and RXR 
genes are constitutively expressed except for the RARβ gene whose 
expression is up-regulated by RA treatment (Chambon, 1996) 
1.2.5 RA and cancer 
Deprivation of dietary vitamin A results in an increase in incidence 
of cancers in experimental animals such as leukemias and an abnormal 
rise in myelopoiesis owing to a loss of spontaneous apoptosis which was 
reversed by RA treatment (Bjelke, 1975; Kuwata et al., 2000). Mutations 
in the RAR and RXR genes occur rarely. A perplexing number of RAR and 
RXR isoforms present in mammalian cells mediate the processes of 
growth inhibition of retinoids. The expression of RARβ gene is inhibited 
in some cancers and its re-expression restores growth arrest in response 
to RA (Liu et al., 1996). Transgenic mice expressing anti-sense RARβ gene 
develop lung cancers, although the exact mechanisms is unclear (Berard 
et al., 1996). One of the well-defined mutations that involve RARs is a 
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reciprocal translocation that occurs between the RARα (human 
chromosome 17) and the promyelocytic leukemia (human chromosome 
15) in some forms of acute promyelocytic leukemia (APL) (de The et al., 
1991). Despite this translocation the resultant fusion protein, PML-RARα, 
responds to RA treatment and leukemic cell growth are successfully 
controlled in APL patients (Chomienne et al., 1990). 
Based on this observation, an oncogenic role for the chimeric 
PML–RARα product has been suggested. The PML protein forms a nuclear 
body consisting of several IFN-inducible genes, ubiquitin ligases and other 
proteins with indeterminate functions. It is known to collaborate with 
p53 tumor suppressor and is also implicated in DNA repair, regulation of 
apoptosis, antigen presentation and viral replication. The PML gene is 
induced by IFNs via a STAT1 dependent pathway and implicated in the 
antiviral actions of IFNs (Kalvakolanu, 2004). 
1.2.6 Growth suppressive effects of retinoids 
Retinoids inhibit pro growth transcription factor E2F to suppress 
growth in some cell types (Lee et al., 1998). The other known effects of 
retinoids include their inhibition of the transcription factor AP1 (Fanjul et 
al., 1994). It is likely that retinoids inhibit tumor growth by blunting the 
expression of AP1dependent pro-growth genes. The growth suppressive 
effects of synthetic retinoids are mediated by a RAR-RXR dependent and 
independent manner (Liu et al., 1996). One of the retinoids, 4-HPR, 
showed an excellent in-vitro activity against tumor cell lines and in animal 
models with one of its actions involving mitochondria related cell death 
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pathways, activately translocating the orphan nuclear receptor TR3 from 
nucleus to mitochondria, and the consequent release of cytochrome c to 
induce apoptosis (Li et al., 2000). In one of the scenarios, interestingly, 
induction of caspase-dependent cleavage of the ubiquitous transcription 
factor Sp1 by certain synthetic retinoids occurs independent of 
transcription to activate apoptosis (Piedrafita and Pfahl, 1997). On a 
similar note, a number of reports of synthetic retinoids inducing cell 
death by a p53-dependent or caspase-dependent manner has been 
recorded (Sun et al., 1999).  
Although primarily developed for cancer therapy, the receptor 
selective retinoids may also be valuable in the treatment of other human 
diseases such as type II diabetes, psoriasis and acne (Thacher et al., 2000). 
Clinically, retinoids are useful in the treatment of APL, and primary 
cancers of the skin, and head and neck. Although less efficacious against 
advanced cancers, retinoids can reverse pre-malignant lesions and the 
development of second primary tumors in head and neck cancers and 
Xeroderma pigmentosum (Hansen et al., 2000). 
1.2.7 Cross talk between IFNs and RA  
Although IFN and RA use different signalling pathways, a cross talk 
between their growth suppressive pathways exists. PML-RARα, a mutant 
chimeric retinoic acid receptor found in certain acute promyelocytic 
leukemias responds to RA (Wang et al., 1998). Interestingly, this mutant 
receptor is induced by IFNs and has been reported to participate in the 
anti-cellular action of IFN-α (Chelbi-Alix et al., 1998; Nason-Burchenal et 
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al., 1996). As mentioned earlier, PML forms a nuclear body consisting of 
several IFN-inducible gene products (Gaboli et al., 1998; Gongora et al., 
1997). PML is induced by IFNs and its promoter contains STAT1 binding 
sites (Pelicano et al., 1997). In certain IFN-resistant cells, RA induces 
STAT1 levels resulting in an enhancement of IFN-responses and a mutant 
STAT1 inhibits RA-induced differentiation in embryonic stem cells 
(Gianni et al., 1997; Kolla et al., 1997; Matikainen et al., 1997). RA has also 
been shown to induce some ISGs directly (Pelicano et al., 1997). RA is 
known to induce the expression of the RIG-G gene (Yu et al., 1997), a 
member of the ISG54 family. However, it is not yet known whether RIG-G, 
like p56, also regulates mRNA translation.  A more compelling connection 
between IFN and retinoid-like receptors comes from a recent study that 
reports that in the liver and macrophages, liver X receptor (LXR), a 
structural homologue of retinoid receptors (RXR), regulates expression of 
the genes involved in cholesterol metabolism. LXRs also appear to be 
markers for atherogenesis. In response to microbial pathogens, the 
cellular toll-like receptors (TLR), which bind to bacterial and viral 
products, such as LPS, flagellae, and dsRNA, stimulate expression of the 
IFN-β gene (Toshchakov et al., 2002). Though these receptors are known 
to activate multiple pathways and their corresponding transcription 
factors, IRF3 is the most significant transcriptional regulator for IFN-β 
gene induction. Among the ten known TLRs, TLR3 and TLR4 stall 
cholesterol metabolism in a ligand dependent manner. In particular, IRF3 
inhibits transcriptional activity of LXRs by combining the promoter 





Figure 1-2: Antiproliferative and proapoptotic effects induced by 
IFN/RA 
A) In untreated cells, the Akt pathway is functional and results in cell 
proliferation.  
B) When the cells are treated with the combination of IFN/RA, it blocks Akt, 
Bcl-xL and Bfl-1 resulting in the release of cytochrome c from mitohcondria 
as well as upregulation of p21 and p27 eventually resulting in cell cycle 





There have been reports of a possible overlapping mechanism, 
shifting gears back to the clinical studies of the IFN/RA combination for 
cancer treatment, as mentioned briefly earlier. Experimental studies have 
shown that the IFN/RA combination is a more potent inhibitor of cell 
growth than either drug alone (Lindner et al., 1997; Moore et al., 1994). In 
locally advanced squamous cell carcinomas of the skin and cervix and 
small cell lung carcinomas the combination of 13-cis RA and IFN-α2a 
showed significantly higher overall clinical response, compared to single 
agents (Ruotsalainen et al., 2000). IFN/RA has only modest effects on 
metastatic cancers (Stadler et al., 1998). However, these cancers are also 
resistant to other modes of therapy. Lack of response in these studies 
could be owing to the doses used, the stage of the disease, and a low 
pharmacologic availability of IFN/RA in the tumor microenvironment. In 
summation, although persuasive anti-tumor effects of IFN/RA in vitro and 
in vivo are known, the molecular bases for such synergistic action are not 
clearly understood. Since the IFN and RA induced toxicities are non-
overlapping, it makes them a good combination for clinical use. Figure 1.2 
gives a more comprehensive view of the possible eventual downstream 







1.3 GRIM-19  
1.3.1 Identification 
The above mentioned characteristics and molecular signalling 
pathways employed by IFNs and RA led Angell et al., resort to devising a 
strategy to isolate genes that may be exclusive in the apoptotic pathway 
executed by the combination of IFN and RA treatment. (Angell et al., 
2000). In this study, they employed an anti-sense technical knock-out 
screen which allows the isolation of cell death-associated genes based on 
their selective inactivation by over-expression of antisense cDNAs. 
Because the antisense mRNA silences gene expression of death-specific 
genes, transfected cells would survive in the presence death inducers, i.e. 
the combination of IFN and RA. Several Genes associated with Retinoid-
IFN induced Mortality (GRIM) was identified using this approach. One 
such protein is GRIM-19. Its 552-base pair cDNA encodes a 16- kDa 
protein. Antisense expression of GRIM-19 conferred a strong resistance 
against IFN/RA-induced death by the reduction of the intracellular levels 
of GRIM-19 protein. However, in this study, they reported that GRIM-19 is 
primarily a nuclear protein. Whereas, our experiments indicate very 
clearly that GRIM-19 is present only in the mitochondrial inner 
membrane (see results section; Figure 3.1 and 3.2). Similar studies’ 





1.3.2 Chromosomal location 
Using Fluorescence In-Situ Hybridization, the chromosomal 
localization of GRIM-19 was mapped to be at p13.1–p13.2 (Chidambaram 
et al., 2000). Apparently, this locus has been shown to host a number of 
tumour suppressive genes such as ICAM-1, Notch 3, and Stau that can 
suppress prostate tumour cell growth (Gao et al., 1999). It is good to 
recollect from the earlier headings that IFNs regulate some tumour 
suppressors. In addition, the IFN regulatory factor-1 (IRF-1) and IFN 
consensus sequence binding protein (ICSBP) have tumour suppressor 
functions (Holtschke et al., 1996). The finding that GRIM-19 is an IFN/RA 
regulated protein and its chromosomal localization led the authors to 
propose that GRIM-19 might be a novel tumour suppressor. 
 
 
1.3.3 Domain architecture of GRIM-19 
According to a study conducted by Lu and others using truncation 
mutants of GRIM-19, (Lu and Cao, 2008) they predict as shown in Figure 
1.3, the plausible domain organization of the protein. As do most 
Figure 1-3: Domain architecture of GRIM-19 
Predicted functional domains of GRIM-19. Arrow marks represent positions of 





mitochondrial proteins, GRIM-19 also hosts a mitochondria-targeting 
sequence on its N-terminal which helps to recruit the protein to the 
mitochondria. Based on the results of this study, the authors classify the 
region encompassed between amino acids (a.a) 20-30 and 40-60 as 
regions playing a vital role in the formation of the trans-membrane alpha 
helix of the protein; 70-80 and a.a 90-100 as important for the 
maintenance of mitochondrial potential; and regions spanning a.a 134-
144 could be essential for the assembly of Complex I of the mitochondria. 
Also represented in the figure is the residues that are mutated in the three 
GRIM-19 mutants characterized in this study. These mutants were 
identified from human tumour samples by Nallar et al., which conferred 
the inhibitory nature to GRIM-19 to oppose STAT3-induced cellular 
transformation (Nallar et al., 2013). These mutations are L71P, L91P, 
A95T. The last mutation, T113A is a modification of a potential 
phosphorylation site identified through a proteomic screening study 
((Palmisano et al., 2007).      
1.3.4 Studies on Interaction with other proteins 
After the identification of GRIM-19, there have been a number of 
studies which report the interaction of GRIM-19 with other proteins. 
Here, we will look into each of them to provide a comprehensive overview 






A yeast two hybrid (Y2H) screen showed that GRIM-19 interacts 
with the serine protease HtrA2 (Ma et al., 2007). The group further went 
on to characterize this interaction in mammalian cells and the effect of 
IFN/RA on this interaction. HtrA2 belongs to a family of mammalian 
serine proteases which localize to the mitochondria (Suzuki et al., 2001). 
In mammalian cells, inhibitors of apoptosis proteins (IAPs) block caspase 
activation. One such protein, the XIAP, inhibits caspase-9. HtrA2 degrades 
XIAP to alleviate the inhibition of caspases (Hegde et al., 2002; Martins et 
al., 2002; van Loo et al., 2002). In this study, they show that the 
interaction is weaker at steady state and that IFN/RA enhances the 
interaction of HtrA2 and GRIM-19 for augmenting cell death.  
The physiologic relevance of GRIM-19 and HtrA2 to IFN/RA-
induced cell death has been shown using multiple approaches. Down 
regulation of either protein is sufficient for preventing cell death and a 
signal-induced degradation of XIAP. Similarly, a catalytically inactive 
HtrA2 mutant fails to augment cell death and the inactivation of XIAP. In 
addition, the results prove that recombinant GRIM-19 can promote the 
protease activity of HtrA2 in vitro. Thus it is shown that GRIM-19 and 
HtrA2 are mutually dependent on each other for executing cell death. The 
PDZ domain of HtrA2 is critical for regulating its activity. The isolation of 
the c-terminal 133 a.a of HtrA2 as a binding partner for GRIM-19 suggests 
that GRIM-19 associates with the PDZ to promote HtrA2 activity. 
Interestingly, they also show the relevance of these interactions to an 
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oncogenic process using the vIRF1 protein of HHV8. Earlier, studies have 
shown that vIRF1 transforms oncogenically NIH3T3 cells and represses 
IFN gene expression. Studies have shown that vIRF1 binds to GRIM-19 
and inhibits apoptosis (Seo et al., 2002). Ma et al., have shown that vIRF1 
disrupts the HtrA2 and GRIM-19 interactions, thereby ablating the 
IFN/RA induced anti-XIAP activity. vIRF1 is not a resident of 
mitochondria. However, it seems to leak into cytoplasm during IFN/RA 
treatment, for preventing XIAP degradation. Thus, the vIRF1 protein 
appears to have evolved for ablating specific cellular innate defence 
mechanisms that prevent virus replication and cellular transformation. 
Finally, they also report that vIRF1 disrupts these interactions to override 
GRIM-19-induced apoptosis.  
1.3.4.2 P16ink4a 
Previously, a proteomic analysis revealed that GRIM-19 also 
interacts with the cell cycle inhibitor CDKN2A (p16Ink4a) (Sun et al., 
2010). P16 is a tumor suppressor, and mutations in its gene sequence or 
epigenetic repression of its expression have been described in a number 
of tumors. The activity of CDK can be blocked by CDK inhibitors, which 
fall within the two protein families Kip/Cip and Inhibitor of CDK kinase 
(INK). The INK4 family is made up of four proteins p15, p16, p18 and p19, 
which have been shown to interact with CDK4/6 in order to suppress 
cyclin-dependent phosphorylation of the retinoblastoma (RB) protein 
(Ruas and Peters, 1998). RB is a very well studied tumor suppressor and 
is known to inhibit the expression of proliferation-associated genes by 
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binding to the transcription factor E2F1 (Dyson, 1998). Sun et al., using 
MCF-7 cells, which lack endogenous p16, show that exogenous p16 
expression led to significant repression of genes required in S-phase. This 
seems to occur because p16 prevents cyclin D1 association with CDK4 
and subsequent expression of E2F1-responsive genes. Indeed, in the 
presence of GRIM-19, the association of p16 with CDK4 was high and 
caused a decrease in cyclin D1-bound CDK4. This effect was reversed by 
GRIM-19 depletion. Importantly, GRIM-19 and p16 co-expression 
synergistically suppressed E2F1-dependent gene expression resulting in 
cell cycle arrest. The physiological relevance of this interaction is further 
supported by in vivo experiments in which p16 and GRIM-19 co-
expression caused a dramatic reduction in tumor size. However, since 
expression of GRIM-19 alone suppressed E2F1-driven transcription, it is 
possible that GRIM-19 is a novel E2F1 inhibitor. Even so, the mechanism 
underlying this inhibition has not been defined. In this study, the authors 
showed that deletion of the fourth ankyrin-like repeat or introduction of 
clinically observed mutations, abolished p16 interaction with GRIM-19 
along with its ability to synergistically repress E2F1-driven transcription 
and tumour growth. This was the first report to identify a function for 
GRIM-19 in cell cycle control and to propose a functional interaction 
between two unrelated tumour suppressors. 
1.3.4.3 GW112 
A protein previously found to be over expressed in tumors of the 
digestive system, GW112 – has been shown to interact with GRIM-19 
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reducing its ability to mediate apoptotic cell death (Zhang et al., 2004). It 
was shown that GW112/OLFM4 is expressed at relatively low levels in 
normal tissues, including prostate, colon, breast and pancreas. However, 
its expression was dramatically higher in pancreatic, stomach and colon 
cancer tissues. Gene reporter experiments revealed that GW112/OLFM4 
localized mainly in the cytoplasm but some foci could be observed in the 
nucleus as well. Interestingly, most of the cytoplasmic GW112 co-
localized with a mitochondrial marker. Since GW112 was found to 
interact with GRIM19 in yeast two-hybrid assay, the authors then 
explored its role in inducing apoptotic cell death. Indeed, overexpression 
of GW112 was sufficient to reduce hydrogen peroxide and IFN-β/RA-
induced apoptosis and apoptotic gene expression. The authors also 
demonstrated that overexpression of GW112 was capable of promoting 
tumor growth in vivo, as assessed by injecting mice with slow growing 
TRAMP-C1 prostate cancer cells expressing GW112. These results were 
further substantiated by another study that compared GW112 mRNA 
expression levels in colon, breast and lung cancer tissues with those of 
matched non-cancerous tissue (Koshida et al., 2007).  A sample 
comparison revealed that the mRNA levels of GW112 were increased in 
90%, 68.8% and 84.6% of the cases analyzed for colon, breast and lung 
cancer tissues, respectively. For colon and breast cancer tissues, high 
GW112 mRNA expression levels were present even in the early stages of 
disease. In the case of lung cancer, it was shown that GW112 levels were 
significantly higher in squamous cell carcinomas than in 
adenocarcinomas. In vitro experiments by the group show that in SBC-1 
 28 
 
lung cancer cells, GW112 knock-down by siRNA dramatically decreased 
their growth capacity. A recent study explored more carefully the link 
between GRIM-19 and GW112/OLFM4, and their influence on tumor cell 
invasion and metastasis (Huang et al., 2010). In human gastric cancer 
SGC-7901 cells, upregulation of GRIM-19 suppressed the expression of 
GW112/OLFM4 resulting in decreasing the binding activity of nuclear 
factor-κB (NF-κB). NF-κB was previously shown to bind to the 
GW112/OLFM4 promoter and to regulate its expression. In the study by 
Huang et al., in vitro assays revealed that when GRIM-19 was upregulated, 
the ability of cells to adhere to Matrigel was significantly decreased. 
Metastatic assays in nude mice demonstrate that SGC-7901 cells over 
expressing GRIM-19 gave rise to fewer visible liver metastases. As cell 
invasion and metastasis are dependent on the cells' capacity to degrade 
extracellular matrix, the authors investigated the effect of GRIM-19 in the 
expression of matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type 
plasminogen activator (u-PA) and vascular endothelial growth factor 
(VEGF), which are known to mediate this process. The authors observed 
that when GRIM-19 was upregulated, the cells secreted less MMP-2, MMP-
9, u-PA and VEGF, leading them to propose that the inhibitory effect of 
GRIM-19 in gastric cancer metastasis is, at least in part, achieved through 
down regulation of these proteins. 
1.3.4.4 Disruption of E6/E6AP complex 
Previous studies had shown a down-regulation of GRIM-19 in 
primary human cervical cancers with restoration of GRIM-19 inducing 
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tumor regression (Zhou et al., 2009).  The induction of tumor suppressor 
protein p53 ubiquitination and degradation by E6 oncoportein of high 
risk-human pappiloma virus (HPV) through forming a stable complex 
with E6AP is considered as a critical mechanism for cervical tumor 
development. Another recent study by the same group (Zhou et al., 2011) 
investigated the potential role of GRIM-19 in rescuing p53 protein and 
inducing cervical cancer cell apoptosis. The protein levels of GRIM-19 and 
p53 in normal cervical tissues and cervical cancer tissues from patients 
with non-metastatic squamous epithelial carcinomas were analyzed. Co-
immunoprecipitation and GST pull-down assays were performed to 
examine the interaction of GRIM-19 with 18E6 and E6AP in vivo and in 
vitro respectively. To examine the disruption of E6/E6AP complex by 
GRIM-19, the competition of 18E6 with E6AP in binding GRIM-19 was 
observed by performing competition pull-down assays. As a result, the 
levels of GRIM-19 and p53 were concurrently down regulated in cervical 
cancers. The restoration of GRIM-19 was able to induce ubiquitination 
and degradation of E6AP, and disrupt the E6/E6AP complex through the 
interaction of N terminus of GRIM-19 with both E6 and E6AP, which 
protected p53 from degradation and promoted cell apoptosis. Tumor 
xenograft studies also revealed the suppression of p53 degradation in 
presence of GRIM-19. Through these data, authors suggested that GRIM-
19 can block E6/E6AP complex, and synergistically suppressed cervical 





Nucleotide oligomerization domain 2 (NOD2) functions as a 
mammalian cytosolic pathogen recognition molecule, and variants have 
been associated with risk for Crohn disease. NOD2 functions as an anti-
bacterial factor limiting survival of intracellular invasive bacteria, to gain 
further insight into the mechanism of NOD2 activation and signal 
transduction. Barnich et al. performed yeast two-hybrid screening and 
demonstrated that GRIM-19 interacts with endogenous NOD2 in HT29 
cells. GRIM-19 is required for NFκB activation following NOD2-mediated 
recognition of bacterial muramyl dipeptide. GRIM-19 is also shown to 
control pathogen invasion of intestinal epithelial cells. GRIM-19 
expression was decreased in inflamed mucosa of patients with 
inflammatory bowel diseases. The authors propose that GRIM-19 may be 
a key component in NOD2-mediated innate mucosal responses and serve 
to regulate intestinal epithelial cell responses to microbes (Barnich et al., 
2005). 
 
1.3.4.6 STAT3  
One of the most promising and highly reported interactions of 
GRIM-19 has been with STAT3. GRIM-19 directly interacts with STAT3, 
inhibiting its gene stimulatory function (Lufei et al., 2003; Zhang et al., 
2003). STAT3 is constitutively active in a number of human cancers either 
by autocrine growth factors or activated oncogenes (Buettner et al., 
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2002). Activated STAT3 induces the expression of a number of cellular 
proto-oncogenes, including c-myc, c-fos and c-met (Yang et al., 2005) cell 
cycle-regulating proteins, such as cyclin D1, cyclin B1 and CDK1/cdc2 
(Bromberg et al., 1999) and anti-apoptotic proteins, suchas B-cell 
lymphoma protein 2 (Bcl-2),myeloid cell leukemia sequence 1 (mcl-1) 
and Bcl-XL (Buettner et al., 2002). All of these are known to promote 
tumor growth. Zhang and others in their study showed that STAT3 bound 
to GRIM-19 in unstimulated cells and that the amount of STAT3 
coimmunoprecipitated with GRIM-19 increased after IFN-β/RA 
treatment. Remarkably, this interaction is restricted to STAT3, as 
experiments performed failed to detect any interaction between GRIM-19 
and STAT1, STAT2 or STAT5, despite their abundant expression in the 
cells used. The authors further demonstrated that GRIM-19 inhibited 
STAT3-induced gene expression, but not its activation or ability to bind to 
DNA. By mutation analysis, the authors were able to map the 
transactivation domain (TAD) as the region on STAT3 targeted by GRIM-
19, and that the phosphorylation of a serine residue at position 727 
(S727), within the TAD, was essential for binding. Considering the known 
role of activated STAT3 in tumor growth, it is tempting to predict that 
GRIM19 inhibition of STAT3 is anti-oncogenic. Another study, by Lufei et 
al., also found that GRIM-19 bound to STAT3 inhibiting it. However, the 
authors proposed that such an inhibition of STAT3 occured by impeding 
its translocation to the nucleus. It remains to be clarified exactly how 
GRIM-19 inhibits STAT3 function. 
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Later, two studies explored in more detail the tumor suppressive 
role of GRIM-19 through interaction with STAT3 (Kalakonda et al., 2007a; 
Kalakonda et al., 2007b). In one of these studies, the authors examined 
GRIM-19 function in the presence of constitutively active STAT3. Chronic 
tyrosyl phosphorylation of STAT3, rendering the protein constitutively 
active, was sufficient to induce oncogenic transformation and has been 
described in a number of human tumors and tumor cell lines (Bromberg 
et al., 1999; Buettner et al., 2002). The authors showed that GRIM-19 
counteracted constitutive STAT3-induced cellular transformation and 
suppressed the expression of genes involved in cell proliferation. In 
another study, it was shown that GRIM-19 was able to suppress src-
induced cellular transformation. The src family of tyrosine kinases is 
known to control several cellular activities, including motility and 
invasion (Martin, 2001). The current study unveiled that in the presence 
of GRIM-19, the number of src-transformed soft-agar colonies 
significantly decreased and these were much smaller as well GRIM-19 
was also able to inhibit src-induced cell motility and growth in vitro, and 
tumor formation in vivo. The authors demonstrated that GRIM-19 
inhibition of src-induced cellular transformation was mediated by 
downregulation of a number of STAT3-dependent genes. However, not all 
of the GRIM-19 effects observed were dependent on STAT3, as GRIM-19 
inhibition of src-induced phosphorylation of cellular proteins still 
occurred even when STAT3 was knocked-down. Actually, the study 
demonstrated that GRIM-19 dramatically suppressed src-induced tyrosyl 
phosphorylation of cortactin, an F-actin-bundling protein that localizes to 
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podosomes and lamellipodia, which may explain the suppressive role of 
GRIM-19 on src-induced cell motility (Sun et al., 2009). These studies 
highlight that GRIM-19 functions as a tumor suppressor seems to occur at 
multiple levels and that the mechanisms underlying these are still far 
from clear. 
Interestingly, it was also reported that STAT3 regulates a 
metabolic function in the mitochondria as a modulator of mitochondrial 
respiration (Wegrzyn et al., 2009). It was observed that STAT3 was 
present in the mitochondria of cultured cells and primary tissues, 
although in a smaller amount than in the cytosol. Importantly, 
mitochondrial STAT3 was shown to regulate complexes I and II, as the 
activities of these were significantly decreased in STAT3 knock-out cells. 
These roles were dependent on STAT3 targeting to mitochondria and 
phosphorylation of S727, but had no relationship with its classical 
function in the nucleus (Wegrzyn et al., 2009). Another study showed that 
this mitochondrial STAT3 is also essential for Ras-induced cellular 
transformation (Gough et al., 2009). Expression of oncogenic Ras (H-
RasV12) conferred to cells the ability to grow into colonies in soft agar, 
which was impaired without STAT3. Noticeably, STAT3 function was 
dependent on S727 but not on phosphorylation of a tyrosine residue at 
position 705 (T705) or DNA-binding domains. These results were also 
verified for the other members of the Ras family, N and K-Ras. 
Mitochondrial STAT3 was also essential for tumor growth in vivo and 
seemed to be involved in the metabolic shift characteristic of cancer cells. 
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Having known of the results of these studies on GRIM-19 and that of 
STAT3’s role in mitochondria, it is indeed tempting to characterize the 
dependency of mito-STAT3’s function on GRIM-19. The forthcoming 
paragraphs also throw some light on GRIM-19 recruiting STAT3 to the 
mitochondria. Bearing these in mind, plausible mechanisms and 
knowledge gaps are covered in the discussion section.  
Recently, another study brought new insights into how GRIM-19 
restrains cell growth via STAT3 inhibition (Nallar et al., 2010). It was 
found that a motif in the N terminus of GRIM-19 protein was essential for 
its function as a tumor suppressor. This motif is formed by the four amino 
acids glutamic acid, aspartate, methionine and proline (QDMP) and 
exhibits structural similarities with some viral RNA proteins. Point 
mutations in the DMP residues strongly impaired the ability of GRIM-19 
to suppress colony formation in soft-agar in comparison to the wildtype 
protein. Mutation in the Q residue also caused loss of the ability to 
suppress anchorage-independent growth, but the results were not as 
dramatic as those obtained with the other mutants. In addition, it was 
previously reported that GRIM-19 inhibits cell motility (Kalakonda et al., 
2007a), a very prominent feature of cancer cells that is required for 
metastasis. On a similar line, in the current study, authors reported that 
mutants lost the ability to suppress cell motility as assessed by wound-
healing assays. It was also demonstrated that, unlike the wild-type 
protein, these mutants were incapable of restraining cell growth. These 
results clearly reveal that the tumor suppressive function of GRIM-19 
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occurs in different cellular processes. However, the authors claimed that 
the results obtained with the mutants cannot be explained by altered 
localization of these within the cells, since immunofluorescence and cell 
fractionation experiments revealed that they were present in the nucleus, 
mitochondria and cytoplasm just like the wild-type protein. This last 
finding is highly disputable since a) the mutations were most likely done 
in the N-terminal region that hosts the mitochondrial targeting sequence 
and b) they report that the wild-type protein was found in the nucleus 
and cytoplasm apart from the mitochondria which may not reflect the 
right localization in itself. Our own results and others stand evidence for 
this.  
Similarly, a tumor-derived mutation in the N terminus, which was 
previously described by a different group (Maximo et al., 2005) that 
results in a lysine to asparagine substitution at residue 5 (K5N), also led 
to the failure of GRIM-19 to inhibit colony formation in soft-agar and limit 
cell growth (Nallar et al., 2010). The in vitro data was further supported 
by in vivo experiments in which it was shown that mutant-expressing 
tumors grew significantly faster than those expressing the empty vector 
or wild-type GRIM-19. To explore in more detail the mechanisms on the 
basis of the observations for the mutant proteins, the authors analyzed 
their ability to suppress STAT3-dependent gene expression. As expected, 
while the wild-type protein clearly inhibited the expression of STAT3-
responsive genes, this anti-STAT3 activity was dramatically reduced in 
some of the mutants. This anti-STAT3 activity was determined not only 
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through real-time PCR and reporter gene assays but also by expressing a 
constitutively active STAT3 in cells and then evaluating the effect of the 
mutants in STAT3-induced gene expression. The authors performed an 
additional experiment where the effect of the selected mutants was 
assessed on cellular transformation induced by src, which is a known 
STAT3 activator. As anticipated, the mutant lacking the N terminus 
completely lost the anti-transforming activity observed with wild-type 
GRIM-19. Immunoprecipitation experiments demonstrated that this loss 
was due to their inability to interact with STAT3. 
1.4 GRIM-19 AND CANCER 
1.4.1 Physiological significance of the interaction between STAT3 
and GRIM-19: Clinical aspects 
Apart from these studies discussed above, there are numerous 
other studies which report the significance of the interaction of GRIM-19 
and STAT3 in several carcinomas. For instance, Zhou et.al, observed 
through immunohistochemical (in 108 breast samples) and western 
blotting analysis (in 20 breast cancer tissues) that GRIM-19 expression 
was severely impaired in breast carcinoma and that there was a 
corresponding increase in the expression of STAT3. The reduction in 
expression of GRIM-19 was associated with lymph node metastasis, 
advanced tumor node metastasis stage and triple negative phenotype 
(Zhou et al., 2013). Various other researchers have also shown that 
activated STAT3 plays a critical role in the pathogenesis of breast cancer, 
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including its metastatic progression and response to therapy. High 
concentrations of activated STAT3 inversely correlated with a complete 
pathologic response of breast cancers to neoadjuvant chemotherapy. 
Activation of STAT3 significantly modulated the biological and clinical 
behaviour of breast cancer (Diaz et al., 2006; Ranger et al., 2009).  
A similar scenario was reported by Li et.al, wherein 
downregulation of GRIM-19 was associated with hyper activation of p-
STAT3 in hepatocellular carcinoma (HCC). GRIM-19 and p-STAT3 
expression levels were analyzed in HCC and adjacent non tumorous liver 
tissues (ANLT) by immunohistochemistry, Western blot analysis, and RT-
PCR.  the expression of GRIM-19 protein was predominantly located in 
the cytoplasm with weak staining in the nucleus in ANLT, but only located 
in the cytoplasm in HCC tissues. HCC samples exhibited low levels of 
GRIM-19 and moderate to high levels of p-STAT3 expression. In contrast, 
ANLT was characterized by high levels of GRIM-19 and low levels of p-
STAT3 expression (Li et al., 2012). 
Extending the relationship between GRIM-19 and STAT3 to 
cervical cancers, Zhou et al., show that reduction in GRIM-19 protein 
levels occur in a number of primary human cervical cancers. 
Consequently, these tumors tend to express a high basal level of STAT3 
and its downstream target genes. More importantly, using a surrogate 
model, they show that restoration of GRIM-19 levels re-establishes the 
control over STAT3-dependent gene expression and tumor growth in vivo. 
GRIM-19 suppressed the expression of tumor invasion and angiogenesis-
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associated factors to limit tumor growth. Tumor samples from mice when 
subjected to Western blot analysis and RT-PCr revealed that the 
expression of STAT3, Cyclin B1 and Bcl2-L1 were decreased in the 
presence of GRIM-19. In addition, expression of Survivin, an antiapoptotic 
protein regulated by STAT3, was also strongly diminished. Apart from 
this, proliferation-associated antigen Ki67’s expression was extremely 
reduced in tumors expressing GRIM-19 compared to control tumors. 
Lastly, Western blot analysis revealed similar results to a study referred 
much earlier in the section that the expression of GRIM-19 significantly 
suppressed the expression of VEGF and matrix metalloproteases, MMP-2 
and MMP-9, involved in tumor invasion (Zhou et al., 2009).  
Another study by Zhang et al. inclined towards the translational 
aspect of cancer therapy reports that co-expressed Stat3-specific shRNA 
and GRIM-19 synergistically and more effectively suppresses prostate 
tumor growth and metastases when compared with treatment with either 
single agent alone. As mentioned earlier, persistent activation of STAT3 
and its overexpression contribute to the progression and metastasis of 
several different tumor types. For this reason, STAT3 is a reasonable 
target for RNA interference mediated growth inhibition. Blockade of 
STAT3 using shRNA could significantly reduce prostate tumor growth in 
mice but was not able to fully ablate target gene expression in vivo, owing 
to the idiosyncrasies associated with shRNAs and their targets. To 
enhance the therapeutic efficacy of Stat3-specific shRNA, the group 
applied a combination treatment involving expression of GRIM-19 as an 
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inhibitor of STAT3 and Stat3-specific shRNAs that were used to create a 
dual expression plasmid vector in vitro and in mouse xenograft models in 
vivo. The study concludes that the simultaneous use of two specific, but 
mechanistically different, inhibitors of STAT3 activity exerts enhanced 
antitumor effects than either single agent alone (Zhang et al., 2008). A 
very similar study conducted on thyroid cancer cells in vitro and in vivo 
reports that simultaneous expression of pSi-Stat3-GRIM-19 in SW579 
cancer cells was found to significantly suppress the proliferation, 
migration and invasion in vitro and tumor growth in vivo, when compared 
to the controls either Stat3-specific siRNA or GRIM-19 alone (Wang et al., 
2014). 
In line with these translation efforts, another group, Okamoto et al. 
tried another approach to suppress tumour growth. They used the nona-
arginine (R9)-protein transduction domain (R9-PTD) as a protein carrier 
to induce high levels of GRIM-19 expression in vitro and in vivo. They 
generated an R9-PTD-containing GRIM-19 fusion protein (rR9-GRIM19) 
and successfully induced over expression in cancer cells. Analysis of the 
expression of downstream molecules of STAT3 confirmed that in vitro 
rR9-GRIM19 treatment of constitutively activated STAT3 (STAT3c) cancer 
cells significantly reduced STAT3-dependent transcription. Moreover, 
intra-tumoral injections of rR9-GRIM19 in STAT3c cancer-bearing mice 
significantly suppressed tumor growth. These results lead the authors to 
suggest that intra-tumoral injections of rR9-GRIM19 have potential as a 
novel anticancer therapy in STAT3c cancer due to their ability to inhibit 
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STAT3-mediated signal transduction without major systemic side effects 
(Okamoto et al., 2010).  
Another study on parallel areas with clinical significance 
demonstrates that GRIM-19 expression was lower in patients with 
radiotherapy-resistant tumors compared to patients with radiotherapy-
sensitive tumors. In order to further investigate the effects of GRIM-19 
expression on the radiation response in gastric cancer cells, they 
established BGC-803 clones stably expressing exogenous GRIM-19. It was 
found that the percentage of apoptotic cells was higher in cells expressing 
GRIM-19 than untransfected cells post-radiation treatment. Furthermore, 
caspase-3, -8, and -9 activity was significantly increased in GRIM-19-
expressing cells compared to untransfected cells after radiation. Finally, 
the study demonstrates that expression of GRIM-19 in BGC-803 cells 
suppresses accumulation of STAT3. Taken together, these data may 
indicate that GRIM-19 expression sensitizes BGC-803 cells to radiation, 
and this is likely due to suppression of STAT3 accumulation. Summing up, 
the results show that GRIM-19 expression might be a useful therapy to 
enhance apoptosis in gastric cancer cells in response to radiation 
treatment (Bu et al., 2013).  
Apart from a number of studies reporting the linkage of GRIM-19 
and STAT3 expression levels in various cancers, there are numerous 
independent studies which report the abnormality of GRIM-19 in several 
carcinomas. The passages below mention aim to cover majority of the 
findings reported. Alchanati et al. report a severe to complete loss of 
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GRIM-19 in a number of human renal cell carcinomas (RCC). More 
importantly, they show the relevance of these data to RCC growth, 
wherein down regulation of GRIM-19 provides growth advantage and 
over-expression enhances cell death via an augmentation of STAT3 
dependent gene activation (Alchanati et al., 2006).  In another study, the 
authors investigated GRIM-19 expression pattern which appeared to 
correlate with hepatocellular carcinoma (HCC) invasive properties. 
Downregulation of GRIM-19 in the hepatic and HCC cell lines enhanced 
adhesive and invasive potential of these cells. While dissecting the 
possible mechanisms by which GRIM-19 mediates tumor invasion, they 
suggest a suppressive effect of GRIM-19 on HCC invasion via modulating 
epithelial–mesenchymal transition (EMT) and cell contact inhibition. 
GRIM-19 has hence been proposed as a new potential target for adjuvant 
treatment of aggressive and invasive HCCs besides surgical resection 
(Hao et al., 2012). 
That downregulation of GRIM-19 promotes growth and migration 
of human glioma cells has been demonstrated by observing GRIM-19 
mRNA and protein expression being markedly lower in gliomas than in 
control brain tissues, which negatively correlated with the malignancy of 
gliomas (Zhang et al., 2011). They also show that downregulation of 
GRIM-19 in glioma cells significantly enhanced cell proliferation and 
migration, whereas overexpression of GRIM-19 showed the opposite 
effects (Zhang et al., 2011).  Lower expressions of GRIM-19 in lung 
cancers were reported by two groups (Fan et al., 2012; Wang et al., 2011) 
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while others reported that upregulation of GRIM-19 provided resistance 
to metastasis and suppressed tumour invasion in gastric cancer cell lines 
and oral carcinomas (Huang et al., 2010; Li et al., 2014). Among the 
differentially expressed proteins in malignant and benign adrenocortical 
tumors, GRIM-19 levels werefound to be significantly lower in malignant 
tumors (Kjellin et al., 2014).  Mechanistic insights into the downstream 
factors of GRIM-19 in glioblastoma cell lines have identified hypoxia-
inducible factor 1α (HIF1α) as a potential candidate.  The study (Liu et al., 
2013) shows that downregulation of GRIM-19 promotes HIF1α synthesis 
in a STAT3-dependent manner, which acts as a potential competitive 
inhibitor for von Hippel-Lindau (pVHL)–HIF1α interaction, and thereby 
prevents HIF1α from pVHL-mediated ubiquitination and proteasomal 
degradation (Liu et al., 2013). Taken together, they conclude that GRIM-
19 could be a potential tumor suppressor gene, performing its function in 
part via regulating glioblastoma metabolic reprogramming through 
STAT3-HIF1α signaling axis. Interestingly, one study reported that 
alternatively spliced forms of GRIM-19 were detected in kidney tumor 
tissues with intron 3 by reverse transcriptase PCR. This splicing variant 
was found in kidney tumor tissues but not in matched normal tissues. 
Furthermore, the research also found that in addition to GRIM-19, the 
protein levels of NDUFS3, which is another mitochondrial complex I 
subunit, were also diminished in kidney tumor tissues when compared 
with paired normal tissues. The authors suggested that the alternative 
splicing forms of GRIM-19 were tumor tissue specific (He and Cao, 2010).  
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Yet another study provided evidence for an observation that 
monoallelic loss of GRIM-19 sufficient to induce squamous cell carcinoma 
in mice. The authors generated a genetically modified mouse in which 
Grim-19 could be conditionally inactivated. Deletion of Grim-19 in the 
skin significantly increased the susceptibility of mice to chemical 
carcinogenesis, resulting in development of squamous cell carcinomas. 
These tumors had high Stat3 activity and an increased expression of 
Stat3-responsive genes. With regard to the mitochondrial function, loss of 
Grim-19 also caused mitochondrial electron transport dysfunction, 
resulting from failure to assemble electron transport chain complexes and 
altered the expression of several cellular genes involved in glycolysis 
(Kalakonda et al., 2013). These observations add further proof to the 
critical role of GRIM-19 as a tumor suppressor.  
Consistent with its regulation by IFNs that are key in immune 
responses, an interesting study that investigates the pathogenesis of 
H5N1 viral infection which is associated with the ability of the virus to 
induce apoptotic cell death, reports that H5N1 virus is able to up-regulate 
the expression GRIM-19 in human monocyte-derived macrophages 
(hMDMs). The percentage of apoptotic cells was significantly decreased in 
H5N1-infected GRIM-19 depleted hMDMs, which was also associated with 
a decrease of BH3-interacting domain death agonist cleavage and 
apoptosis-inducing factor (AIF) release to the cytosol. Furthermore, 
neutralizing-IFN-β Ab is able to suppress GRIM-19 expression in H5N1-
infected cells resulting in a decrease in apoptotic cell number, indicating 
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that IFN-β secreted by H5N1-infected hMDMs regulates GRIM-19 
expression leading to apoptosis (Ekchariyawat et al., 2013). This is 
consistent with other studies referred to earlier, reporting that GRIM-19 
expression could be induced by IFN-β and RA.  
1.5 MITOCHONDRIAL FUNCTIONS OF GRIM-19 
At the time of the discovery of GRIM-19 protein, 42 subunits of 
Complex I of the mitochondrial respiratory chain were defined with 35 
nuclear encoded genes and 7 mitochondrially encoded proteins. Fearnly 
et al., using a mass spectrometric analysis revealed that GRIM-19 is a 
subunit of Complex I of the mitochondria which did not correspond to any 
known subunit of the complex assembly at the time. However, this study 
does not provide any evidence at the cellular level for the localization of 
GRIM-19 (Fearnley et al., 2001). A study referred to earlier, by Angell et 
al., the founders of the GRIM-19 protein, reveal a predominantly nuclear 
staining and possibly punctae in the cytoplasm corresponding to the 
mitochondria (Angell et al., 2000). Nevertheless, the images provided are 
far from convincing. As this has been dealt with in our study, a 
comparison and discussion of both the results are done in the discussion 
section.  
During one of the early studies on the interaction between GRIM-
19 and STAT3, the authors tried to investigate the cellular localization of 
GRIM-19 and report that it is majorly found as punctae in the cytoplasm 
and aggregates around the perinuclear region coinciding with COX 
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protein. They also state that the results show a minor distribution in the 
nucleus. Both the fractions witnessed an increase in the presence IFN/RA 
(Lufei et al., 2003). The group further claims that GRIM-19 suppresses 
STAT3 via functional interaction thus preventing STAT3 from entering 
the nucleus and up-regulating downstream genes in the cascade. 
However, there are a few glitches in the experimental design and the 
immunofluorescence results that are discussed in detail in the discussion 
section.  
The same group further took to in vivo analysis of the function of 
GRIM-19 by generating a mouse knock out model. In this study, they 
report that homologous deletion of GRIM-19 causes embryonic lethality at 
embryonic day 9.5. GRIM-19-/- blastocysts show retarded growth in vitro 
and, strikingly, display abnormal mitochondrial structure, morphology, 
and cellular distribution (The quality of the image does not allow any 
conclusion to be made with enough confidence. As this also contradicts 
with our results, more detailed discussion is made under the discussion 
section). Although, they claim to have re-examined the cellular 
localization of GRIM-19 in various cell types and found its primary 
localization in the mitochondria, the results for the same are not clear and 
the mitochondria looks highly fragmented not to mention the staining 
being non-specific (Huang et al., 2004). A subsequent study by the group 
involved knockdown of GRIM-19 in Xenopus laevis embryos. A severe 
deficiency in heart formation was observed, and the deficiency could be 
rescued by reintroducing human GRIM-19 mRNA. The mechanism 
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involved was further investigated. It was found that the activity of NFAT, a 
transcription factor family that contributes to early organ development, 
was downregulated in GRIM-19 knockdown embryos. Furthermore, the 
expression of a constitutively active form of mouse NFATc4 in these 
embryos rescued the heart developmental defects. Since NFAT activity is 
controlled by a calcium-dependent protein phosphatase, calcineurin, it 
suggests that calcium signaling could be disrupted by GRIM-19 
knockdown. Indeed, both the calcium response and calcium-induced 
NFAT activity were found to be impaired in the GRIM-19 or NDUFS3 
(another complex I subunit) knockdown cell lines. They also showed that 
NFAT can rescue expression of Nkx2.5, which is one of the key genes for 
early heart development (Chen et al., 2007).  Of note is the result of the 
same group in a study that shows that GRIM-19 is necessary for 
maintenance of mitochondrial membrane potential with the use of 
truncation mutants (Lu and Cao, 2008). This also has contradictions with 
what we observe in our data and hence is taken up for discussion in the 
upcoming sections. 
In the most recent study by Chen et al., from the same group, the 
authors observe that GRIM-19 +/- mice were more prone to urinary tract 
infection and that the macrophages from these mice have compromised 
mitochondrial complex I activity and increased ROS levels (Chen et al., 
2012). In addition, production of pro-inflammatory cytokines, such as 
interleukin (IL)-1, IL-12, IL-6, and interferon (IFN)-γ induced by both 
bacterial infection and lipopolysaccharide (LPS) and 
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monodansylcadaverine treatment, is also decreased in the GRIM19+/- 
macrophages. Inhibition of mitochondrial RC activity by inhibitors 
showed a similar reduction on the cytokine production. 
1.5.1 Does GRIM-19 recruit STAT3 to mitochondria? 
Previous studies conducted in the background of necroptosis, 
indicated that GRIM-19 mediated translocation of STAT3 to the 
mitochondria plays an essential role in the execution of the process. 
Tumor necrosis factor (TNF) can induce necroptosis, wherein inhibition 
of caspase activity prevents apoptosis but initiates an alternative 
programmed necrosis. The activity of receptor-interacting 
serine/threonine-protein kinase 1 (RIPK-1) is required for necroptosis to 
proceed, with suppression of RIPK-1 expression or inhibition of RIPK-1 
activity with necrostatin-1 preventing TNF-induced necroptosis. 
Downstream from the TNF receptor, the generation of reactive oxygen 
species at the mitochondria has been identified as necessary for the 
execution of necroptosis; with antioxidants and inhibitors of 
mitochondrial complex I preventing TNF-induced cytotoxicity. However, 
components of the signaling pathway that lie between activated RIPK-1 
and the mitochondria are unknown. In this study they demonstrate that 
during TNF-induced necroptosis, STAT3 is phosphorylated on serine 727, 
which is dependent on RIPK-1 expression or activity. The 
phosphorylation of STAT3 induced interaction with GRIM-19, a subunit of 
mitochondrial complex I, with a resultant translocation of STAT3 to the 
mitochondria, where it induces an increase in ROS production and cell 
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death. As much as the idea could be thought of as a reasonable one, there 
is not much of raw data that is presented by the study except for western 
blots whose quality still stands highly arguable (Shulga and Pastorino, 
2012).     
A recent study by Tammineni et al., showed convincingly through a 
thorough in vitro analysis that the import of STAT3 into the mitochondria 
depends on GRIM-19. The authors showed that GRIM-19 acts as a 
chaperone to recruit STAT3 into inner mitochondrial membrane. In 
addition, GRIM-19 was shown to enhance the integration of STAT3 into 
complex I. A S727A mutation in STAT3 reduced its import and assembly 
even in the presence of GRIM-19 (Tammineni et al., 2013).  
1.6 HYPOTHESIS 
We hypothesized that GRIM-19 may play an important part in the 
dynamics of mitochondria, eventually acting as an inducer of cell death 
under stressful conditions. Since it was shown to be a part of Complex I, it 
could play an important role in the generation of ROS which may be, in 
part, the way in which it executes cell death through the IFN/RA cell 
death pathway. In the case of mutations found in GRIM-19 from tumour 
samples, these functions could be altered leading to abnormal 
proliferation and eventually cancer.  
 




With the pool of knowledge as mentioned above, when we 
embarked on our study, our aims were as follows: 
 To unambiguously determine the sub cellular localization of GRIM-19 
using protease protection assay and alkaline conditions on the 
mitochondrial fraction and immunofluorescence assays. 
 To investigate if GRIM-19 has a role in mitochondrial dynamics by 
forming a part of the fission-fusion machinery of the mitochondria. 
This was studied using the FRAP assay under GRIM-19 over-
expression and KD conditions (Fluorescence Recovery After 
Photobleaching)  
 To study the mitochondrial functions of GRIM-19 such as its role in the 
production of ROS, maintenance of mitochondrial potential and 
production of ATP using dyes such as DHE and TMRM with 
Fluorescence Assorted Cell Sorting (FACS)  
 To characterize certain tumour derived mutations of GRIM-19 with 
respect to its mitochondrial functions using Site-directed mutagenesis 
and subsequently the anomalies they cause in the normal functioning 
of the mitochondria.   
 50 
 
Chapter 2  MATERIALS AND METHODS 
2.1 GENE CLONING 
2.1.1 RNA extraction 
Total RNA was extracted from HEK 293T cells using Trizol 
(Invitrogen) according to the instructions provided by the manufacturer.  
Briefly, a total of 1 ml of Trizol was added to one well of a 6-well plate of 
HEK 293T cells. The cells were homogenized and incubated at room 
temperature for 5 min to allow nucleoproteins to dissociate before adding 
200 μl chloroform. The mixture was shaken for 15 sec and incubated at 
room temperature for 2-3 min, followed by centrifugation at 12,000x g for 
15 min at 4 °C in order to separate the aqueous and organic phases. An 
aliquot of 500 μl aqueous phase was transferred to a new tube and mixed 
with 500 μl isopropyl alcohol. The mixture was incubated at room 
temperature for 10 min and centrifuged for 15 min at 12,000xg at 4 °C. 
The supernatant was discarded and the pellet containing RNAs was 
washed with 70% ethanol and centrifuged at 7,500x g for 5 min at 4 °C. 
After the pellet was briefly air dried, it was dissolved into 20 μl Diethyl 
pyrocarbonate (DEPC) water. The isolated RNAs can now be used for 





2.1.2 Reverse transcription polymerase chain reaction (RT-PCR) 
SuperScriptTM Reverse Transcriptase from Invitrogen was used to 
carry out RT-PCR. Firstly, a mixture of RNA template (11.5 μl), OligodT (1 
μl) and dNTP (1 μl) was incubated at 65 °C for 5 min followed by chilling 
on ice. Subsequently, 5 X First strand buffer (4 μl), 0.1 M DTT (2 μl) and 
RNAas outTM (0.24 μl) were added and the mixture incubated for 2 min at 
42 °C. Subsequently, SuperScript RTaseTM (0.25) was added to the mixture 
and incubated for 50 min at 42 °C and 15 min at 70 °C. The synthesized 
cDNA was used for PCR immediately or be stored at -80 °C. 
Components Volume (µl) 
RNA template(1 µg/µl) 2 
dNTP (10 mM) 1 
DTT (0.1 M) 2 
Oligo-dT18 (100 µM) 1 
Reverse transcriptase (200 U/µl)* 0.25 
5 × first strand buffer 4 
Sterile distilled water 10.75 
Total 20 
Table 2-1: Reverse transcription reaction 
 
2.1.3 Polymerase Chain Reaction (PCR) 
Amplification of the gene constructs from the cDNA was carried 
out using DyNAzymeTM EXT DNA polymerase (Finnzymes, Thermo 
Scientific). The reaction adopted, the PCR cycle parameters and the 






Table 2-2: PCR reaction 
 
Table 2-3: PCR cycling parameters 
 
 
Table 2-4: Sequences of primers for cloning 
 
2.1.4 DNA ligation and transformation 
All the genes amplified from the cDNA library or template were 
purified using QIAquick Gel Extraction Kit (Qiagen) after agarose gel 
electrophoresis and then subjected to double restriction enzymatic 
digestion. The restriction enzymes and buffers used in this study were 
Component Volume (μl) 
cDNA template (200ng/μl) 1-2 
Forward primer (10 nM) 0.5 
Reverse primer (10 nM) 0.5 
dNTP (10 nM) 0.5 
10 X 514 Buffer 2.5 
DyNAzymeTM EXT 0.5 
Double-distilled water Top up to 25 μl 
Total 25 
Cycle Step Temperature (°C) Time 
1 Initialization 95 3 min 
 Denaturation 95 30 s 
25 Annealing 55 40 s 
 Extension 72 1 min ( 1min/kb) 
1 Final elongation 72 5 min 
1 Final hold 4 ∞ 






























purchased from NEB. The reaction was incubated at 37 °C for 2-6 hours. 
The components of restriction digestion reaction were shown in Table 2.5 
Table 2-5: Double digestion restriction system 
 
The digested products were purified once again using QIAquick Gel 
Extraction Kit (Qiagen) and GRIM-19 was inserted into EGFP-N1 vector 
(Clonetech)to fuse GFP into the C terminus of GRIM-19, a pXJ40 vector 
with different tags namely, FLAG, GFP, c-myc or BFP (kindly dononated by 
Dr. Low Boon Chuan, Department of Biological Sciences, National 
University of Singapore) which fuses these tags to the N terminus of 
GRIM-19and C-Flag vector (Addgene) to fuse FLAG to the C terminus of 
GRIM-19. The restriction enzyme sites used for the cloning of these 
plasmids are mentioned in Table 2.4.  
The ligation reaction was incubated at 4 °C overnight. The 
components added in the reaction are shown in Table 2.6. After ligation, 
the product was transformed into DH5α or TOP10 competent cells. The 
products of ligation were added into 100 μl DH5α or TOP10 competent 
cells and incubated on ice for 30 min. Subsequently, the mixture was 
heated at 42 °C for 90 sec and cooled on ice for 3 min. This was followed 
by addition of 1 ml of LB medium (Conda) and incubation at 37 °C shaker 
for 1 hour. After incubation, the mixture was centrifuged and supernatant 
Component Volume (μl) 
Purified PCR product 16.5 
Restriction enzyme 1 0.5 
Restriction enzyme 2 0.5 
10 X Buffer 2 
BSA 0.5 
Total volume 20 
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was removed. The pellet was resuspended to be spread and grown on LB 
agar plate supplemented with appropriate antibiotics for around 16 hours 
and the resulting colonies on the plate were picked for plasmid extraction. 
Table 2-6: Ligation reaction 
 
Plasmid extraction was performed using miniprep plasmid 
extraction kit (Axygen) according to the protocol from the manufacturer. 
Double restriction enzymatic digestion was performed to the plasmids to 
verify the insertion and the plasmids with insertion were subject to DNA 
sequencing analysis to confirm the fidelity of the inserted segment.  
2.1.5 DNA sequencing 
DNA sequencing was carried out using ABI PRISM BIG DYETM 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). 
The sequencing PCR mixture and cycling parameters are shown in Table 





Component Volume (μl) 
Double digested PCR product 7 
Double digested vector 0.5 
T4 ligase (Promega) 0.5 
10 X  T4 ligase Buffer (Promega) 1 
Total volume 10 
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Table 2-7: DNA sequencing reaction 
 
 Table 2-8: Cycling parameters for DNA sequencing reaction 
 
The PCR products were mixed with 20 μl of 3 M NaOAc (pH 4.6) 
and 50 μl of 95% ethanol and incubated at room temperature for 10 min. 
The samples were centrifuged at 13,200 rpm at 4 °C for 10 min. The 
supernatant was removed and the pellet was washed twice with 500 μl of 
70% ethanol, centrifuging at 13,200 rpm for 5 min after each wash. The 
pellet of PCR product was air-dried at room temperature and dissolved in 
15 μl HiDi and subject to automated sequencing on the ABI 377 sequencer 
system. 
2.1.6 Site-directed mutagenesis 
FLAG-GRIM19 and EGFPN1-GRIM-19 single point mutations were 
carried out by site-directed mutagenesis using QuickChangeTM Site-
Directed Mutagenesis Kit (Stratagene, CA). The experiments were 
performed following the manufacturer’s instruction. The components 
Component Volume (μl) 
Terminator Ready Reaction Mix 2 
1 mM sequencing primer 3 
5 X  sequencing reaction buffer 4 
Template DNA (200-500 ng/μl) 1 
Double-distilled water 10 
Total volume 20 
Cycle Temperature (°C) Time 
1 95 1 min 
 95 10 s 
25 50 5 s 
 60 1 min 
1 4 ∞ 
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added into the PCR reaction are shown in Table 2.9. The PCR cycle 
parameters are shown in Table 2.9. 
Table 2-9: Site-directed mutagenesis PCR reaction system 
 
Table 2-10: Site-directed mutagenesis PCR cycle parameters 
 
The PCR products were subsequently digested by Dpn I restriction 
enzyme (10 U/μl) for 2 hours at 37 °C and the digested products were 
transformed into DH5α or TOP10 competent cells for plasmid extraction. 
The mutations were verified by DNA sequencing. 
2.2  WESTERN BLOT  
Cells were washed by 1x PBS and placed on ice immediately. For 
10-cm plates, 1 ml RIPA buffer (20 mM Tris-Cl at pH 8.0, 125 mM NaCl, 
0.5% NP-40, 5% glycerol) with phosphatases inhibitors (20 mM NaF, 0.2 
mM Na3VO4, 2 mM EDTA) and protease inhibitors (Sigma) was added to 
cover all the cells in the plate, which was then put on ice for 30 min with 
Component Volume (μl) 
Template plasmid (50 ng/μl)  1 
Primer forward (10nM)  1 
Primer reverse (10nM)  1 
dNTP (10nM) 1 
10 × buffer  5 
Pfu Turbo DNA polymerase  1 
Sterile distilled water  40 
Total volume 50 
Cycle Step Temperature (°C) Time 
1 Initialization 95 1 min 
 Denaturation 95 1 min 
18 Annealing 60 1 min 
 Extension 72 6 min ( 1min/kb) 
1 Final elongation 72 10 min 
1 Final hold 4 ∞ 
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occasional shaking. After the incubation, cells were transferred to a new 
tube and then centrifuged at maximum speed for 30 min at 4 °C. The 
supernatant was collected and the protein concentration was determined 
using Bradford Protein Assay reagent (Bio-Rad) according to 
manufacturer’s instructions. An appropriate amount of 6 × SDS loading 
dye was added to each sample and boiled at 95 °C for 15 min before 
loading for SDS-PAGE. The proteins separated on SDS-PAGE in a SDS-
running buffer (12.5 mM Tris-Cl [pH 7.4], 96 mM glycine, 1.7 mM SDS) 
were immediately transferred onto a PVDF (polyvinylidene difluoride) 
membrane. The membranes were then incubated in 5% BSA or 5% 
skimmed milk in TBST (20 mM Tris-Cl [pH 7.4], 137 mM NaCl, 0.1% 
Tween-20) for 1 hour, followed by washing with 1x TBST thrice, 10 min 
each time. After washing, the membranes were incubated in primary 
antibodies diluted in 1x TBST over night at 4 °C or at room temperature 
for 1 hour. After primary antibody incubation, the membranes were 
washed by 1x TBST again thrice and subsequently incubated in secondary 
antibodies for 1 hour at room temperature. Washing was carried out 
again at the end of secondary antibody incubation as described above. 
Proteins on membranes were detected by an enzyme-substrate reaction 
using an ECL kit (Pierce) and exposure to FUJI medical X-Ray film 
(FUJIFILM).  
GRIM-19 antibody used for western blot was purchased from abcam 
(Anti-GRIM19 antibody [6E1BH7] ab110240). The product is a well 
validated one with clear bands at the predicted molecular weight of 
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GRIM-19 (around 16-17 kDa). Further to this, I have also carried out 
preliminary assays to verify the authenticity of the purchased antibody by 
western blots and immunoflourescence assays.   
2.3 MITOCHONDRIAL EXTRACTION  
HEK 293T, HeLa and MEF cells cultured in 10-cm dishes were 
washed with 1x PBS before being harvested with a pre-cold 
mitochondrial extraction buffer (220 mM mannitol, 70 mM sucrose, 20 
mM Hepes-KOH, pH 7.5, 1 mM EDTA, 0.5 mM PMSF, and 2 mg/ml BSA) 
supplemented with protease inhibitors including 0.7 μg/ml pepstatin, 0.5 
μg/ml leupeptin and 2.2 mg/ml Aprotinin. The cells were scrapped and 
transferred to a new 1.5 ml tube; subsequently, the cells were passed 
through a 25-G syringe (BD) for ten times on ice. The homogenized cells 
were centrifuged for 15 min at 4 °C, 1000xg. The supernatant was 
transferred to a new tube followed by another 20 min centrifugation at 4 
°C, 10,000x g to pellet the mitochondria. The supernatant fraction 
contains the cytosolic protein.  
2.4 MITOCHONDRIAL MEMBRANE ANALYSIS ASSAY AND 
PROTEINASE K DIGESTION  
For mitochondrial membrane analysis and proteinase K digestion 
assay, mitochondria of HeLa cells were pelleted according to the method 
described previously. Mitochondrial samples were resuspended in freshly 
prepared 0.1 M Na2CO3, pH 11.5, and incubated on ice for 30 min with 
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vortexing every 10 min. After the incubation, membranes were 
centrifuged down to the pellet at 100,000 g for 30 min at 4 °C, and the 
supernatant was collected as inter-mitochondrial membrane space and 
matrix proteins.  
For proteinase K digestion assay, isolated mitochondria were 
resuspended in mitochondrial isolation buffer and incubated with 
different proteinase K concentrations on ice for 30 min. PMSF was added 
to stop the digestion and the samples were precipitated by TCA. Pellets 
were resuspended in RIPA buffer (20 mM Tris-Cl [pH 8.0], 125 mM NaCl, 
0.5% NP-40, 5% glycerol, 20 mM NaF, 0.2 mM Na3VO4, 2 mM EDTA, and 
protease inhibitors) for 30 min and subjected to SDS-PAGE and Western 
blotting.  
2.5 IMMUNOFLUORESCENCE  
HeLa cells were seeded on sterilized glass coverslips in 12-well 
plates 24 hours before transfection with indicated plasmids or siRNAs. 
After transfection, cells were cultured for the indicated time and fixed by 
freshly prepared 4% PFA (paraformaldehyde) for 10 min at room 
temperature. PFA was removed after fixation followed by 2 times wash 
with PBS and the coverslips were then incubated with 3% BSA + 
0.1~0.5% Triton X-100 in PBS for 30 min at room temperature for 
blocking and permeabilization. After the incubation, coverslips were 
washed using PBS for 3 times and followed by incubation with primary 
antibodies diluted in 3% BSA for 1 hour at room temperature. After 
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primary antibody incubation, coverslips were washed again and 
incubated with fluorescence conjugated secondary antibodies for 45 min 
at room temperature. The secondary antibodies used were Alexa Fluor 
dye-conjugated IgG (488,568 and 642)(Molecular Probe, Invitrogen) After 
incubation, coverslips were washed with 1x PBS and DNA was stained by 
Hoechst 33342 (Invitrogen) for 15 minutes at room temperature. Cells 
stained by various dyes were mounted onto glass slides using 
FluorSaveTM reagent (Calbiochem) and preserved at 4 °C for further 
analysis.  All fluorescent images were acquired on Ultraview Vox spinning 
disc confocal system (PerkinElmer) equipped with a 60× 1.2 N.A. 
objective (Olympus). The images were processed using Volocity Suite 
(PerkinElmer). 
2.6 LIVE CELL IMAGING AND FLUORESCENCE RECOVERY AFTER 
PHOTOBLEACHING (FRAP)  
For live cell imaging, HeLa cells seeded in a 35mm-glass-bottom 
dish with different treatments were incubated at 37 °C, 5% CO2 chamber 
equipped on the microscope, and time lapse imaging was taken on 
Ultraview Vox spinning disc confocal system (PerkinElmer). VolocityTM 
(PerkinElmer) was used to control all the parameters used for image 
acquisition.  
For FRAP analysis, HeLa cells stably expressing mito-Red were 
transfected with the indicated plasmids. The use of mito-Dsred for FRAP 
analysis is a validated method wherein the RFP is fused with a 
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mitochondrial protein to avoid usage of chemical stains that may interfere 
with the result of the experiment (Frohlich et al., 2013). Cells were placed 
on the live imaging system described above, and the laser line of 561 nm 
was used to bleach a 2 × 2 μm2 area placed on the fiber of mitochondrial 
network. 20 sec of recovery time for each bleaching was used to make 
sure the recovery had reached their plateau. 60 FRAP curves with each 
treatment were analyzed by measuring the intensities of mito-Red 
fluorescence in the photobleached area.  
2.7 ROS AND MITOCHONDRIAL POTENTIAL DETECTION 
To test levels of ROS and mitochondrial potential, fluorescent 
indicator DHE (Invitrogen) and TMRM were used. Cells were harvested, 
washed in PBS and stained with 5 µM DHE or 50nM TMRM dye for 30 min 
or 20min respectively at 37 °C in the dark. Fluorescence was measured 
immediately with LSRFortessa (BD Biosciences), and the data was 
analyzed with the FACSDiva version 6.2 software (BD Biosciences). The 
fluorescence intensity of the red signal in DHE/TMRM stained cells 
indicates ROS level or the mitochondrial potential respectively. A total of 
10,000 cells were counted in each population. 
2.8 ATP PRODUCTION ASSAY  
ATP was measured by using the ATP determination kit (Molecular 
Probes) according to manufacturer’s instruction. In brief, HeLa cells 
transfected with control or GRIM-19 siRNAs were washed with 1 × PBS 
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and placed in ice-cold ATP buffer (20 mM Tris-HCl, PH7.5, 0.5% Nonidet 
P-40, 25 mM NaCl, and 2.5 mM EDTA) for 5 min. Lysates were then 
centrifuged at 13,000× g for 30 min at 4 °C and supernatants were 
collected and protein concentrations were measured using the Bradford 
Protein Assay reagent (Bio-Rad). ATP levels were determined by using 0.5 
μg of proteins for each reaction and every sample was measured in 
triplicate. 
 
2.9  CELL CULTURE AND TRANSFECTION  
2.9.1 Cell lines  
Human embryonic kidney epithelial cells (HEK 293T), human 
cervical cancer cells (HeLa) were used in the current studies. HEK 293T 
cells were mainly used for the biochemical assays for expression of 
vectors. While, HeLa cells were mainly used for biochemical assays of the 
mitochondrial fractionation and the imaging analyses of mitochondrial 
morphology. 
2.9.2 Cell culture  
HeLa and HEK 293T cells were maintained in Dulbecco’s modified 
Eagle medium (DMEM) (Hyclone), supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Hyclone) and 10U/ml Penicillin-streptomycin 
(Hyclone) unless otherwise noted. All cultures were maintained at 37 °C, 
5% CO2.  
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2.9.3 Transfection  
2.9.3.1 HEK 293T cell line transfection  
Plasmid DNA was introduced into HEK 293T cells using calcium 
phosphate transfection. One day before transfection, cells were seeded in 
10-cm plates. The transfection cocktail including 10 µg of the plasmid 
DNA, 500 µl of 2 × HBS and 50 µl of 2.5M CaCl2 was topped up to 1ml with 
distilled water. After cells reach 50%-60% confluence, the transfection 
cocktail was added directly into the culture medium.  
2.9.3.2 HeLa cell line transfection  
For HeLa cells, EffecteneTM (Qiagen) was used to transfect 
plasmid DNA. At 70%-80% confluence, cells in 12- or 6-well dishes were 
transfected with 6 µl or 10 µl of Effectene reagent mixed with 0.3 µg or 0.4 
µl of plasmid DNA and 2.4 µl or 3.2 µl of enhancer, respectively. PEI was 
also used to transfect HeLa cells. This protocol involved diluting the 
plasmid DNA in 1x PBS at 1µg plasmid DNA per well of a 12 well plate. 
Three times the amount of PEI was added to the diluted plasmid DNA and 
the mixture incubated for 20 minutes. It was later added directly added to 
cells on the corresponding plate. 
2.9.3.3 siRNA transfection using lipofectamine  
Transfection of siRNA into HeLa cells using OligofectamineTM 
(Invitrogen) was performed according to manufacturer’s instructions. 
Briefly, cells at 60%-70% confluences in 12-well plates were changed to 
non-antibiotics medium before they were ready for transfection. A total of 
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3 µl of Lipofectamine 2000TM reagent mixed in 100µl of OPTI for 5 min 
was combined with 120 pmol siRNA mixed in 100 µl of OPTI. The 
transfection cocktail was incubated in room temperature for another 20 
min, followed by adding into cells directly. 48 h after transfection, the 
knockdown efficiency of the target proteins were validated by Western 
blotting or immunofluorescence. All of the siRNA sequences listed in the 
table below were synthesized by Sigma. 
 
GENE shRNA TARGET SEQUENCE 
GRIM-19 
















Chapter 3  RESULTS 
3.1 CHARACTERIZATION OF GRIM-19 FUNCTION ON 
MITOCHONDRIAL MORPHOLOGY AND DYNAMICS 
3.1.1 GRIM-19 localizes to the inner mitochondrial membrane 
Ever since the identification of GRIM-19, its intracellular 
localization has been highly controversial.  The founders of this protein 
suggested a nuclear localization, which was reported by a few other 
groups as well (Angell et al., 2000). However, subsequent research 
indicated mitochondrial localization (Huang et al., 2004). Nonetheless, 
these studies too fail to show convincing data for their claim. This led us 
to investigate and conclude unambiguously the intracellular localization 
of GRIM-19. To do the same, I performed immunostaining with HeLa cells 
using an anti-GRIM-19 antibody to locate endogenous GRIM-19. Figure 
3.1 shows that GRIM-19 localizes to the mitochondria as indicated by 
Tom20, an outer mitochondrial membrane protein. Consistently, Western 
blot analysis revealed that GRIM-19 was present only in the 
mitochondrial fraction and not in the cytosolic fraction (Figure 3.2 A). The 
purity of the mitochondrial fraction is indicated by the non-leakage of 
cytochrome C to the cytosolic fraction and absence of tubulin 
contamination in the mitochondrial fraction. Further to this, I employed 
the Proteinase K protection assay to further ascertain the sub-
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mitochondrial localization of GRIM-19. The Proteinase K digestion led to 
the disappearance of Tom20. The results, as seen from Figure 3.2 C, 
showed that GRIM-19 exhibited a similar pattern to the inner 
mitochondrial membrane protein Tim23, both being protected until 










Figure 3-1: Sub cellular localization of endogenous GRIM-19 
Sub cellular localization of endogenous GRIM-19. HeLa cells were fixed with 4% 
paraformaldehyde and permeablized by 0.5% Triton-X 100 in BSA for 30 min. 
Following this, the cells were stained with an anti-Tom20 antibody or anti-
GRIM-19 antibody. Scale bar: 14µm  
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    B) 











Following Proteinase K digestion, alkaline extraction using Na2CO3 
was performed to study the membrane association of GRIM-19. As shown 
in Figure 3.2 B, GRIM-19 is detected in the mitochondrial pellet portions 
suggesting that GRIM-19 is integrated with membrane, consistent with 
Tim 23, an inner mitochondrial membrane bound protein. On the other 
hand, cytochrome C which is present in the inter-membrane space, 
purifies in the supernatant fraction of the mitochondria. Taken together, 
the Proteinase K protection assay and the alkaline extraction clearly show 
that GRIM-19 is part of the inner mitochondrial membrane. 
Figure 3-2: Sub cellular localization of endogenous GRIM-19 
A) Mitochondrial extraction performed with HeLa cells. Cells were harvested 
using mitochondrial isolation buffer and separated into the mitochondrial (M) 
and cytosolic (C) fractions. VDAC1 and Tubulin were identified as mitochondrial 
and cytosolic markers respectively. Cytochrome C was used to indicate the purity 
of the mitochondrial fraction. This assay shows that Grim19 localizes to 
mitochondria. No detectable amount of protein was found in the cytosol. 
B) Sub-mitochondrial localization of Grim19. Mitochondrial fractions were 
prepared as described in A. This was subjected to alkaline extraction using 
sodium carbonate (P and S represent the Pellet and Supernatant fractions 
obtained after alkaline extraction) or incubated with the indicated 
concentrations of Proteinase K (panel C) and immunoblotted for Tim 23, Tom 20 
as inner and outer mitochondrial membrane markers respectively.  
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3.1.2 Alteration to GRIM-19 does not affect the mitochondrial 
morphology 
Once the endogenous localization of the protein was determined, I 
set out to characterize the over expression constructs of GRIM-19. I had 
designed GRIM-19 plasmids that fused tags on its N-terminal. As shown in 
Figure 3.3 A and Figure 3.3 B, the GFP and Flag tags present on the N-
terminal of GRIM-19 appear to affect its proper localization to 
mitochondria. Instead, the tagged GRIM-19 protein forms abnormal 
punctae in the cytoplasm. This led us to clone constructs with the tags on 
the C-terminal of GRIM-19. When this tagged GRIM-19 were over-
expressed in cells, the localization of the protein was primarily observed 




















Figure 3-3: N-terminal tags affect the localization of GRIM-19 
A) N terminal tags affect the localization of GRIM-19. HeLa cells were 
transfected with either pXJ40 GFP vector or GFP-GRIM-19. Cells were stained 
with Mito Tracker Red before performing live cell imaging. Results show that 
GFP-GRIM-19 forms aggregates/punctae in the cytoplasm devoid of a proper 
cellular localization pattern. However, this does not affect the morphology of 
mitochondria. 
B) HeLa cells were transfected with Flag vector (pXJ40) or Flag-GRIM-19 and 
fixed with 4% paraformaldehyde and permeablized by 0.5% Triton-X 100 in 
BSA for 30 min. Following this, the cells were stained with Anti-Tom20 antibody 
and Anti-Flag antibody. Though GRIM-19 seems to localize to the mitochondria, 
the mitochondrial morphology is affected. Since, this method involves fixing the 
cells, any artefacts should be ruled out (GFP tags utilize live cell imaging and 


















Figure 3-4: C-terminal tags facilitate proper localization of GRIM-19 
A) HeLa cells were transfected with either an EGFP-N1 or GRIM-19-GFP 
plasmid. Cells were stained with Mito Tracker Red before performing live cell 
imaging. Results clearly indicate that GRIM-19 with a tag on the C-terminal can 
localize to the mitochondria without forming aggregates or affecting the 
morphology of the mitochondria. 
B) HeLa cells were transfected with Flag vector (C-FLag) or GRIM-19-Flag and 
fixed with 4% paraformaldehyde and permeablized by 0.5% Triton-X 100 in 
BSA for 30 min. Following this, the cells were stained with Anti-Tom20 antibody 
and Anti-Flag antibody. These results complement the live cell imaging results 




These results also indicated that the over expression of GRIM-19 
using the right tags is critical and does not affect the morphology of the 
mitochondria.  
Since other studies had shown that GRIM-19 knockout mice cannot 
survive beyond E 9.5 (Huang et al., 2004), I was interested in investigating 
the effects of knock down of GRIM-19 in mammalian cells, especially with 
regard to the mitochondria. A lentiviral system was used to generate a 
knock down stable line. Alternatively, I had also designed siRNAs to 
specifically knock down GRIM-19. From Figure 3.5 A and B, it is clear that 
both the methods mentioned above led to a significant depletion of GRIM-
19 protein levels. These were verified by immunostaining as well. From 
the immunofluorescence, our results suggest that depletion of GRIM-19 















Figure 3-5: Effects of GRIM-19 knockdown on mitochondrial 
morphology 
A) HeLa cells were infected with a pLVRNAi lentiviral system for generation of 
stable GRIM-19 knock-down cell line. After selection with 2 µM puromycin for 
cells successfully infected, the cells from control and GRIM-19 siRNA were 
harvested and analyzed using Western blot to confirm the knock down of GRIM-
19 efficiency. As seen from the above figures, shRNA  proved to be efficient in 
knocking down GRIM-19. 
B) HeLa cells were transfected with control siRNA or GRIM-19 siRNA before 
being fixed by 4% paraformaldehyde and permeablizing with 0.5% Triton X-





3.1.3 GRIM-19 does not control mitochondrial dynamics 
As mentioned earlier, mitochondria are highly dynamic organelles 
that constantly undergo fission and fusion (Chan, 2006). Once I confirmed 
that overexpression of or depletion of GRIM-19 does not affect the 
mitochondrial morphology, I was curious to find out if GRIM-19 plays a 
role in mediating mitochondrial dynamics. A Fluorescence Recovery After 
Photobleaching (FRAP) assay is useful in studying the dynamics of 
structures (Day et al., 2012). Hence, I employed the same to analyze the 
effects of overexpression of GRIM-19 and knockdown of it on 
mitochondrial dynamics. However, a significant difference of fluorescence 
recovery levels and fluorescence rates between the control and GRIM-19 
overexpressing cells were not found (Figure 3.6 A and D). Figures 3.6 B 
and C show the mean fluorescence recovery curve individually of both 



































































































I also observed that when the FRAP experiment was performed 
with GRIM-19 depleted cells, the fluorescence recovery levels and rates 
were comparable to that of control knockdown cells, indicating that 
GRIM-19 may not play a role by being part of the mitochondrial dynamics 
machinery. These can be verified from Figures 3.7 A and D which show 
the representative images for the indicated time points during the FRAP 
assay. Figures 3.7 B and C are the compilation of fluorescence recovery 

































n1 vec gfp cntrl  
grim19 gfp 
Figure 3-6: Effects of GRIM-19 over expression on mitochondrial 
dynamics 
A) Representative images of mitochondrial signal recovery in fluorescence 
recovery after photobleaching (FRAP) assay. HeLa cells stably expressing mito-
DsRed were transfected with an EGFP-N1 control vector or a GRIM-19 GFP 
plasmid as indicated.  
B) Live-cell imaging was performed at an interval of 0.5 s. A 2 × 2 μm2 square 
region of interest (ROI) was selected on the mitochondrial fiber and 
photobleached  
C) Representative curves of individual experiments showing the mean recovery 
curve. MitoRed cells were transfected with an EGFP-N1 vector. 
D) Representative curves of individual experiments showing the mean recovery 
curve. MitoRed cells were transfected with GRIM-19 GFP. 
Normalized recovery curves of mito-DsRed signal intensity after 

































































































3.2 EFFECTS OF GRIM-19 ON MITOCHONDRIAL FUNCTIONS 
3.2.1 Depletion of GRIM-19 increases ROS production 
Our aim of the project in large was to characterize the GRIM-19 
protein and dissect its mitochondria-related roles. Following experiments 
that were designed to study the mitochondrial morphology and dynamics, 
I carried out analysis of mitochondrial functions such as production of 
ROS, maintenance of mitochondrial membrane potential and the 
generation of ATP under GRIM-19 knockdown conditions. Firstly, I 


































Figure 3-7: Effects of GRIM-19 knockdown on mitochondrial 
dynamics 
A) Representative images of mitochondrial signal recovery in fluorescence 
recovery after photobleaching (FRAP) assay. HeLa cells stably expressing mito-
DsRed were transfected with control siRNA or GRIM-19 siRNA as indicated. 
Live-cell imaging was performed at an interval of 0.5 s. A 2 × 2 μm2 square 
region of interest (ROI) was selected on the mitochondrial fiber and 
photobleached  
B) Representative curves of individual experiments showing the mean recovery 
curve. MitoRed cells were transfected with cntrl siRNA. 
C) Representative curves of individual experiments showing the mean recovery 
curve. MitoRed cells were transfected with GRIM-19 siRNA. 




by using the DHE dye. The fluorescence of the dye indicates the level of 
ROS in the cells. This fluorescence was measured by Fluorescence 
Activated Cell Sorting (FACS). Quantification analysis revealed that 
knockdown of GRIM-19 increases the ROS levels in the cells by about 
30%. Figure 3.8 A shows the scatter plot as seen from the results of FACS 












































CNTRL KD  GRIM-19 KD 
Figure 3-8: Effects of GRIM-19 KD on mitochondrial function- ROS 
A) Control KD or GRIM-19 KD stable cells were washed with PBS and trypsinized 
and collected in medium containing DHE before analyzing by Flow cytometry. 
Cells were progressively sorted for live and single cells before measuring the 
intensity of DHE which indicates the amount of ROS in the cells.  
B) Bar graph represents the fluorescence intensity of DHE for Control and GRIM-
19 KD cells. Results indicate that knock down of GRIM-19 increases ROS 
production in cells.*P<0.05(student t test). Error bars represent + SEM. 
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3.2.2 Knockdown of GRIM-19 does not alter mitochondrial 
membrane potential 
The next parameter I wanted to study was the alteration of 
mitochondrial membrane potential upon depletion of GRIM-19. To this 
end, I used the TMRM dye, a lipophilic slow potential sensitive membrane 
distribution compound. It distributes in the inner mitochondrial 
membrane driven by the mitochondrial membrane potential. This leads to 
an increase in its fluorescence (Gerencser et al., 2012). In apoptotic cells, 
the reagent is dispersed throughout the cells at a concentration that 
yields a minimum fluorescence when excited. As mentioned earlier, FACS 
was used to measure the fluorescence of TMRM as well. As shown in 
Figure 3.9 A and B, our results show that the read out between 
















































CNTRL KD  GRIM-19 KD 
Figure 3-9: Effects of GRIM-19 KD on mitochondrial function- 
Mitochondrial potential 
A) Control KD or GRIM-19 KD stable cells were washed with PBS and 
trypsinized and collected in medium containing TMRM before analyzing by Flow 
cytometry. Cells were progressively sorted for live and single cells before 
measuring the intensity of TMRM which indicates the mitochondrial potential in 
the cells.  
B) Bar graph represents the fluorescence intensity of TMRM for Control and 
GRIM-19 KD cells. Results indicate that knockdown of GRIM-19 does not affect 
the maintenance of mitochondrial potential.  
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3.2.3 ATP generation is not affected by GRIM-19 knockdown 
Since GRIM-19 was reported to be a subunit of Complex I of the 
mitochondrial respiratory chain (Fearnley et al., 2001), I was interested in 
investigating the effect of depletion of GRIM-19 on ATP production. This 
assay was carried out using the ATP determination Kit (Invitrogen) that 
utilizes the luciferase enzyme activity. The conversion of the substrate 
luciferin to oxyluciferin by the luciferase enzyme requires the presence of 
ATP. Thus the intensity of luminescence will give an indication of the 
amount of ATP present in the cells. Results of this assay upon 
quantification show that there is  no significant difference between cells 







































cntrl sirna Grim-19 KD 
Figure 3-10: Effects of GRIM-19 KD on mitochondrial function- ATP 
Control KD or GRIM-19 KD cells were washed with PBS, collected in ATP Buffer 
and incubated in the same for 5 min followed by centrifugation to obtain the 
lysate. The lysate is then measured for its ATP content using ATP determination 
Kit (Invitrogen). This utilizes the luciferase assay. Bar graph represents relative 
amount of ATP produced. Results indicate that GRIM-19 KD does not 
significantly affect ATP production. 
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3.3 ROLE OF GRIM-19 IN CELL CYCLE 
There have been several reports as mentioned in detail in the 
introduction section, about GRIM-19 knockdown favouring cell 
proliferation and thus leading to cancer (Cheng et al., 2014; Hao et al., 
2012; Li et al., 2012; Zhang et al., 2011; Zhou et al., 2013; Zhou et al., 
2009). This is understandable since GRIM-19 is proposed to be a cell 
death regulator. To look into this at a cell division level, I wanted to 
examine which phase is altered during GRIM-19 knockdown. To this end, 
I fixed control and GRIM-19 knockdown cells and used the PI dye to stain 
the DNA, the amount of which indicates the stage of cell cycle. The 
fluorescence of PI is measured by FACS. As represented in Figure 3.11, 
there was a marked reduction in the percentage of cells in the sub-G1 
phase from 10 % in control knockdown cells to 4.9 % in GRIM-19 KD cells. 
Similarly the G1 phase also shows a reduction from 59.9% in control KD 
cells to 49.6% in GRIM-19 KD cells. A corresponding increase in the 
percentage of cells in G2 was observed as 16.1% in control KD cells to 






















 10%          59.9%     12.7%          16.1% 
   4.9%          49.6%    13.9%           28.8% 
Control KD 
GRIM-19 KD 
Figure 3-11: Effects of GRIM-19 KD on cell cycle 
Control KD stable line cells or GRIM-19 KD cells were fixed using ice cold 70% 
percent ethanol after all floating and attached cells were collected. The cells 
were then treated with RNAse before being stained by PI and subjected to FACS 
analysis. The percentage value in the scatter plots represents the percentage of 




3.4 EFFECT OF IFNΒ/RA TREATMENT ON CELLS 
3.4.1 The combination of IFNβ/RA causes more cell death than either 
drug alone 
GRIM-19 was identified originally from a screen that provided 
resistance to IFNβ/RA treatment. However, to validate this in my hands, I 
resorted to treating HeLa cells with the single agent alone (IFNβ or RA) or 
the combination of both. It is now widely accepted that the combination 
causes more cell death than either drug alone. This was found to be true 
in our trials as well. The various panels labeled with the corresponding 
treatment in Figure 3.12 show that IFNβ alone causes 25% lesser cell 
death and RA alone causes about 40% lesser cell death compared to the 
combination treatment of IFNβ/RA which causes about 50% death of 































Untreated Treated with IFNß only 
Treated with RA only Treated with both IFNß/RA 
Fugure 3-12: Effects of IFNß/RA treatment on cell death 
HeLa cells were subjected to various combinations of treatments. Cells were 
either untreated or Treated with IFNß only at 30ng/ml or RA only at 1µM or a 
combination of both IFNß/RA at the indicated concentrations for 48 hours. After 
48 hours, floating and attached cells were harvested and stained with PI before 
subjecting to FACS analysis. Results clearly show that IFNß/RA combination is 
much more potent in inducing cell death than either drug alone.   
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3.4.2 Treatment with IFNβ/RA causes fragmentation of 
mitochondria but does not change the localization of GRIM-19 
Once the cell death inducing capabilities of IFNβ/RA were studied, 
I was curious to know the effects of this treatment on mitochondrial 
morphology and the localization of GRIM-19. The rationale behind was to 
identify if GRIM-19 is translocated from mitochondria to cytoplasm to 
execute the apoptotic signaling pathway induced by the treatment. HeLa 
cells were treated with IFNβ/RA for 48 hours before being fixed and 
immunostained to detect protein signals. In Figure 3.13, the top panel 
shows untreated cell exhibiting normal mitochondrial morphology 
whereas the bottom panel with treated cells shows fragmented 
mitochondria. One can also observe from these figures that the 

















3.4.3 Knockdown of GRIM-19 provides resistance to IFNβ/RA 
induced cell death 
Although GRIM-19 is shown as an effecter of cell death through the 
IFNβ/RA pathway (Angell et al., 2000), in order to test the dependency of 
this apoptotic signaling on GRIM-19, I decided to treat cells depleted of 
GRIM-19 with IFNβ/RA to see the percentage of rescue of cell death. The 
methodology of the experiment was similar to previously mentioned ones 
as I used PI to detect dead cells by FACS. Indeed, as it is clear from Figure 
3.14, knockdown of GRIM-19 rescues cell death by about 20%. The 
Figure 3-13: Effect of IFNß/RA treatment on the localization of 
GRIM-19 
HeLa cells were either treated or untreated with IFNß/RA for 48 hours at 
30ng/ml (IFNß) and RA (1µM. After the treatment, cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.5 %Triton X 100 for 30 mins 
followed by staining with an anti Grim-19 antibody or Tom20 antibody. Results 
indicate that the mitochondria are fragmented upon IFNß/RA. However, this 
does not change the localization of GRIM-19. Scale bar: 14µm 
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various panels below the quantification graph represent the scatter plots 















3.4.4 Fragmentation of mitochondria caused by IFNβ/RA is partially 
rescued by GRIM-19 KD 
From the previous results two observations are made clear; firstly, 

























cntrl sirna Grim-19 KD 
Control KD GRIM-19 KD 
Figure 3-14: GRIM-19 KD rescues cell death induced by IFNß/RA 
HeLa cells were transfected with cntrl siRNA or GRIM-19 siRNA. After 48 hours, 
the cells were treated with IFNß/RA (at 30ng/ml IFNß and 1µM RA) for 48 
hours. Following this, all cells (floating and attached) were collected and stained 
with PI to identify the dead cells and analyzed by Flow cytometry. Bar graph 
represents the percentage cell death in cntrl and GRIM-19 KD background. 
Results indicate that GRIM-19 KD provides resistance to IFNß/RA induced cell 
death. *P<0.01; Error bars represent+SEM 
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combinatorial treatment causes the fragmentation of mitochondria. My 
next experiment was to examine the effect of this treatment on the 
morphology of mitochondria when GRIM-19 is depleted. Figure 3.15 
shows mitochondrial morphology in control and GRIM-19 KD cells upon 
treatment with IFNβ/RA. It is observed that in the GRIM-19 knockdown 
cells, some mitochondria exhibit normal tubular morphology. A bar graph 
represents the quantification analysis for the percentage of cells 
exhibiting different mitochondrial morphology under the indicated 
treatments. 
  
Untreated cntrl siRNA+IFNβ/RA GRIM-19 
siRNA+IFNβ/RA 
Figure 3-15: Effects of IFNβ/RA on mitochondrial morphology in 
normal and GRIM-19 depleted cells 
HeLa cells were transfected with either control siRNA or GRIM-19 siRNA prior 
to treatment with IFNβ/RA for 48 hours. Cells were stained with MitoTracker 
RED before performing live cell imaging. Normal : *P<0.01; Fragmented *P<0.01 
Scale bar: 14µm 
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3.5 CHARACTERIZATION OF PATIENT TUMOR DERIVED GRIM-19 
MUTANTS 
3.5.1 Mutations in GRIM-19 do not affect the morphology of 
mitochondria 
After a near comprehensive analysis of the wild type GRIM-19, I 
came across a report that had identified mutations in the tumor tissues of 
patients with head and neck cancer. I was enthusiastic to know what the 
possible effects could be of these mutants on the normal functioning of 
the mitochondria. To begin with, these GRIM-19 mutants, i.e. L71P, L91P, 
A95T and T113A were cloned into the appropriate C-terminal tags (Flag 
and GFP). The foremost experiment was to over express these mutant 
proteins into HeLa cells to see the effect of these mutations on the 
mitochondrial morphology. In Figure 3.16, the various panels show these 
mutant proteins with different tags as indicated. As is obvious from the 











































Figure 3-16: Localization of GRIM-19 mutants and their effect on 
mitochondrial morphology 
A) HeLa cells were transfected with either L71P GRIM-19 Flag or L71P GRIM-19 
GFP. As in the first panel, cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.5 % Triton in BSA before staining with Tom20 and Anti-
Flag antibody before staining with Hoechst. In the second panel, cells were 
transfected with L71P GRIM-19 GFP and stained with MitoTracker RED before 
being subjected to live cell imaging 
B) HeLa cells were transfected with either L91P GRIM-19 Flag or L91P GRIM-19 
GFP. As in the first panel, cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.5 % Triton in BSA before staining with Tom20 and Anti-
Flag antibody before staining with Hoechst. In the second panel, cells were 
transfected with L91P GRIM-19 GFP and stained with MitoTracker RED before 
being subjected to live cell imaging 
C) HeLa cells were transfected with either A95T GRIM-19 Flag or A95T GRIM-19 
GFP. As in the first panel, cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.5 % Triton in BSA before staining with Tom20 and Anti-
Flag antibody before staining with Hoechst. In the second panel, cells were 
transfected with A95T GRIM-19 GFP and stained with MitoTracker RED before 
being subjected to live cell imaging 
D) HeLa cells were transfected with either T113A GRIM-19 Flag or T113A GRIM-
19 GFP. As in the first panel, cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.5 % Triton in BSA before staining with Tom20 and Anti-
Flag antibody before staining with Hoechst. In the second panel, cells were 
transfected with T113A GRIM-19 GFP and stained with MitoTracker RED before 
being subjected to live cell imaging 
E) HeLa cells were either transfected with Flag vector or EGFP-N1 as controls. 
For the Flag vector, cells were processed in the same way as mentioned earlier. 
EGFP-N1 transfected cells were stained with MitoTracker RED before 
performing live cell imaging. 
Scale bars for all images:14µm  
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3.5.2 Mutants of GRIM-19 have a similar expression level as that of 
wild type  
My next objective was to clarify if the expression levels of these 
mutants are different or similar to that of wild type protein. HEK 
293Tcells were used for this purpose. The different mutants with their 
tags were over expressed in HEK 293 T cells and  Western blot was run to 
observe their expression levels. The top panels in Figure 3.17 show that 
all the mutants are expressed at comparable levels to that of wild type.  
Proceeding further with the characterization of mutants, my 
interest was to analyze their effects on the production of ROS since our 
previous results showed that knockdown of GRIM-19 increases the ROS 
production. To this end, my strategy was to overexpress the mutants in 
the GRIM-19 knockdown stable line. This was conceived to eliminate the 
possible effects of endogenous GRIM-19. This demands that we verify the 
overexpression of the mutants in the GRIM-19 knockdown stable line 
since there is a possibility of degradation of the mutant proteins by the 
shRNA against wild type GRIM-19. Therefore, I over expressed the GFP 
tagged mutant proteins i.e. L71P, L91P, A95T and T113A in GRIM-19 KD 
stable line and performed western blot. These results are shown in Figure 
3.17 (bottom panel). Expression of the mutant proteins was well 
observed in the knockdown stable line.   
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Figure 3-17: Expression levels of GRIM-19 mutants- L71P, L91P, 
A95T and T113A GRIM-19 
A) 293T cells were transfected with L71P, L91P, A95T or T113A GRIM-19 Flag 
plasmids. Cells were then harvested and subjected to SDS-PAGE. Membranes 
were probed with Tubulin or GRIM-19 Antibody 
B) 293T cells were transfected with L71P, L91P, A95T or T113A or WT GRIM-19 
EGFP-N1 plasmids. Cells were harvested thereafter to run SDS-PAGE. 
Membranes were probed with Anti-GRIM-19 Antibody and Tubulin.  
C) Since the following experiments involve over expressing the mutant GRIM-
19-GFP proteins in the GRIM-19 KD stable cell line, their expression level in the 
same is shown as reference. It is clear that the mutants are expressed in the 
knockdown cells and the level of GRIM-19 KD is also indicated as control in the 
right half of the same figure. GRIM-19 KD cells were transfected with the 
mentioned mutants and harvested after 24 hours for Western blot analysis. 
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3.5.3 Mutant GRIM-19 does not alter the mitochondrial membrane 
potential 
Since the GFP tagged mutants could be successfully over expressed 
in the knockdown stable line, these could now be used to study the effect 
of these mutations on the maintenance of mitochondrial membrane 
potential and the generation of ROS. The measurement was done in a 
similar method to that mentioned earlier in the results section. TMRM dye 
was used to indicate the mitochondrial membrane potential, the intensity 
of which was recorded by FACS. Results as seen from the bar graph in 
Figure 3.18 have not a significant difference between the various mutants 
and wild type GRIM-19. These are validated by the scatter plots seen in 
the same figure that show peaks of TMRM fluorescence for the different 
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T113A GRIM-19 GFP in cntrl KD T113A GRIM-19 GFP in GRIM-19 
KD 
Figure 3-18: Effects of GRIM-19 mutants on mitochondrial functions- 
Mitochondrial potential 
Control KD or GRIM-19 KD stable cells were transfected with the indicated 
plasmids. One day post transfection, cells were washed with PBS, trypsinized 
and collected in medium containing TMRM. Fluorescence intensity of TMRM 
indicates the mitochondrial potential in the cells. This was analyzed by Flow 
Cytometry. Cells were progressively selected to finally analyze 10,000 live GFP 




3.5.4 Mutants of GRIM-19 increase the ROS levels 
As shown before, knockdown of GRIM-19 increases the ROS levels 
of the cell. Having known this, I next wanted to examine the mutants’ 
effect on ROS production. This was measured after over expression of GFP 
tagged mutant GRIM-19 proteins in GRIM-19 KD stable line. DHE dye was 
used to measure the amount of ROS in the cells. GFP and TMRM double 
positive cells were sorted using Flow Cytometry. The results indicate an 
increase in ROS levels in the mutant expressing cells. The level of ROS was 
on an average (between the different mutants) 34.68% more in the cells 
expressing the different mutant forms of GRIM-19 in comparison to the 
GRIM-19 depleted cells. In the corresponding wild type GRIM-19 
expressing cells, there was only a 15.6% increase in ROS levels indicating 
that when wild type GRIM-19 is supplied it could aid in the rescue of ROS 
increase. In other words, there is a rescue of about 22.58% in ROS levels 
when cells are replenished with wild type GRIM-19. These are shown in 
Figure 3.19. The scatter plots represent the peaks of DHE fluorescence in 
the various mutant or wild type or control over expressing cells as 
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Figure 3-19: Effects of GRIM-19 mutants on mitochondrial functions- 
ROS 
Control KD or GRIM-19 KD stable cells were transfected with the indicated 
plasmids. One day post transfection, cells were washed with PBS, trypsinized 
and collected in medium containing DHE. Fluorescence intensity of DHE 
indicates the ROS in the cells. This was analyzed by Flow Cytometry. Cells were 
progressively selected to finally analyze 10,000 live GFP positive single cells. 
GRIM-19 mutants are not able to rescue the increase in ROS caused by the 
knockdown of GRIM-19 whereas Wild type GRIM-19 transfected into GRIM-19 
KD cells reduces the production of ROS. *P<0.05(student t test). Error bars 




Chapter 4  DISCUSSION AND CONCLUSIONS 
4.1 MITOCHONDRIAL LOCALIZATION OF GRIM-19 
A number of groups, from the time of its identification have tried 
to pin point the localization of GRIM-19 inside the cell. The scientists who 
discovered GRIM-19 attributed its cellular localization to the nucleus 
(Angell et al., 2000). However, the immunofluorescence images are far 
from convincing. This could be the result of lack of developments in the 
imaging field at the time. Though subsequent studies projected a partial 
mitochondrial localization of GRIM-19, apart from the wide conviction 
that most of the protein accumulated in the nucleus at the time, these 
studies also had their laws which made the results unreliable. For 
example, in the study by Lufei et al., the authors used a tag on the N-
terminal of the GRIM-19 protein, doing which, we show, affects the 
localization of the protein (Refer Figure 3.3 A and B). The reason that the 
N-terminal tags might affect the localization could be because the 
mitochondria localization signal (MLS) is usually present in the 
Nterminus of a mitochondria targeted protein. Hence, the tags have a 
probability of interfering with the normal translocation to the 
mitochondria. Later on, studies by the same group had ascertained that 
majority of GRIM-19 localizes to the mitochondria. Yet again, now with 
advancement in the imaging techniques, authors failed to provide 
convincing data (Huang et al., 2004; Lu and Cao, 2008). The MitoTracker 
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signal was well detected in the nucleus and the mitochondria in cells of 
both the studies looked highly fragmented not to mention the poor 
quality of the images. Therefore, before embarking on the 
characterization of GRIM-19’s mitochondrial functions, without a solid 
proof for the localization of the protein, it was necessary for us to clarify 
unambiguously, the same. To this end, our results very clearly show that 
endogenous (Refer Figure 3.1) GRIM-19 and the C-terminal tagged GRIM-
19 (Refer Figure 3.4 A and B) localize to only the mitochondria and not 
the nucleus. We have proved this using Western Blot too. GRIM-19 was 
observed only in the mitochondrial fraction and not the cytosolic. 
However, the mitochondrial fraction could be made purer by eliminating 
the possibility of contamination by ER, nucleus, peroxisomes and other 
such organelles. Nevertheless, the cytosolic fraction is relatively pure and 
shows that GRIM-19 does not localize to the cytoplasm. (Refer Figure 3.2 
A). A closer look at the blots would reveal that GRIM-19 is not digested at 
low concentrations of Proteinase K in contrast to Tom20, an outer 
mitochondrial membrane protein which is digested even at very low 
Proteinase K concentrations. Only when Triton X-100 is added to the 
digestion mixture is GRIM-19 digested (Refer Figure 3.2 C). Moreover, it is 
found only in the pellet fraction of mitochondria (Refer Figure 3.2 B) 
whereas cytochrome c is found in the supernatant fraction of the 
mitochondria. These results give a clear understanding of the sub cellular 
localization of GRIM-19. It can now be concluded that it is part of the 




4.2 EFFECTS OF GRIM-19 ON MITOCHONDRIAL MORPHOLOGY AND 
DYNAMICS 
When I overexpressed GRIM-19 with the right C-terminal tags, I 
did not observe any change in the mitochondrial morphology (Refer 
Figure 3.4 A and B). A number of studies have thus far reported the 
downregulation of GRIM-19 in cancer tissues (Zhang et al., 2011; Zhou et 
al., 2013; Zhou et al., 2009). The majority of the studies to date pertain to 
the function of GRIM-19 in cancer and the molecular mechanism involved. 
Very few report its function in the mitochondria. This drove me to 
observe the anomalies in the mitochondria when GRIM-19 is depleted in 
the cells. Figures 3.5 A and B show that GRIM-19 was successfully ablated 
from the cells to a very significant extent. Figure 3.5 B makes clear that 
reduction in GRIM-19 levels do not disrupt the mitochondrial 
morphology. However, since our aim was to conduct a comprehensive 
analysis of the function of GRIM-19 with regard to the mitochondria, I 
moved on to study mitochondrial dynamics under excess and limiting 
amounts of GRIM-19. This was done by FRAP analysis. Consistent with the 
results from the morphology analysis, dynamics study also showed that 
GRIM-19 does not have a role to play in controlling the fission and fusion 
of mitochondria. We concluded this after observing from Figures 3.6 A, B, 
C and D that the recovery of fluorescence of GRIM-19-GFP and GFP vector 
transfected cells do not differ significantly which implies that 
mitochondria are able to divide and unite normally under excess GRIM-19 
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conditions. Similarly, Figures 3.7 A, B, C and D show that control and 
GRIM-19 KD cells do not suffer any difficulty in maintaining their balance 
between fission and fusion. This indicates that GRIM-19 is not part of the 
dynamics controlling machinery. 
4.3 THE ROLE OF GRIM-19 IN MITOCHONDRIAL FUNCTION 
4.3.1 GRIM-19 KD increases the production of ROS 
Though GRIM-19 was identified to be part of mitochondrial 
Complex I (Fearnley et al., 2001), not much has been discovered of its 
specific role in the functions of mitochondria such as ROS production, 
maintenance of mitochondrial membrane potential and generation of 
ATP. In this direction, my first attempt was to check the levels of ROS in 
cells with physiological level of GRIM-19 and those which are depleted of 
the protein. I used the GRIM-19 KD stable cell line and control-shRNA KD 
stable cell line for the analysis. DHE dye was used to indicate the amount 
of ROS present in the cells. Upon measuring the fluorescence of DHE in 
both the samples, it was observed that GRIM-19 KD cells exhibited a 
greater accumulation of ROS than that in the control KD cells (Refer 
Figure 3.8 A and B). Literature shows several studies reporting an 
increase in the ROS levels in cancer cells (Liou and Storz, 2010; Pelicano 
et al., 2004). Our results corroborate with the present findings that 
downregulation of GRIM-19 occurs in cancer tissues. In addition, we 
propose with the backing of our results, that this could be in part by an 
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increase in ROS levels. Further studies are needed to explore how GRIM-
19 KD causes an increase in ROS production.      
4.3.2 GRIM-19 depletion does not affect mitochondrial potential 
My next test was the alteration of mitochondrial potential upon 
removal of GRIM-19.. GRIM-19 KD and control KD cells were stained with 
TMRM, a positively charged fluorescence indicator of mitochondrial 
potential. When the intensity of fluorescence was measured using FACS, I 
was surprised to note that there was no change in the mitochondrial 
potential between the two population of cells (Figure 3.9 A and B). 
Previous studies have reported that GRIM-19 is essential for the 
maintenance of potential (Lu and Cao, 2008). The reason for a 
discrepancy in our results could be because of a few reasons. Firstly, their 
group had used truncation mutants to assess the role of GRIM-19 in 
maintenance of potential. The truncation mutants could have caused 
disturbances to the normal functioning of Complex I. It is not necessary 
that the total absence of GRIM-19 should also exhibit the same effect since 
the result from Lu et al. could have been caused by the toxicity of the 
truncated mutants owing to their misfolding or sorts. Knockdown study 
provides a much more direct evidence of the role of the protein of 
interest, here GRIM-19, than mutant studies. Secondly, the previous group 
had carried out their assays using MCF-7 cells and we had used HeLa cells. 
This could also be the reason for our difference in results pertaining to 




4.3.3 GRIM-19 KD does not hamper ATP production 
Another most important functional aspect of mitochondria is its 
production of ATP. The five complexes in the inner membrane of the 
mitochondria co-ordinate in shuttling electrons between them that finally 
results in the generation of ATP molecules. Since GRIM-19 makes up a 
subunit of Complex I, we wanted to see the effect of GRIM-19 depletion on 
the production of ATP in cells. To this end, using the ATP determination 
kit from Invitrogen, luciferase assay based analysis was carried out to 
reveal the gross amount of ATP in a comparable amount of cells from the 
two sets of samples (GRIM-19 KD and control KD). Figure 3.10, a 
quantification analysis of the data from the experiments conducted 
indicated that GRIM-19 may not be an important factor in the production 
of ATP. Other subunits of Complex I could contribute more significantly to 
ATP production and also compensate for the loss of GRIM-19.  
4.4 EFFECTS OF GRIM-19 DEPLETION IN CELL CYCLE 
GRIM-19 has been proposed to be a cell death regulatory protein 
through the IFNβ/RA pathway. Apart from this, as mentioned earlier, 
several reports have been published that claim that downregulation of 
GRIM-19 is observed in several cancer tissues (Cheng et al., 2014; Li et al., 
2012; Zhang et al., 2011; Zhou et al., 2013; Zhou et al., 2009). Most of 
these studies have been carried out with patient tissue samples. I was 
curious to know at a cellular level how changes in GRIM-19 reflect in cell 
cycle. For this, GRIM-19 KD and control cells were fixed using Propidium 
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Iodide to be followed by FACS analysis. Results as depicted in Figure 3.11 
show that depletion of GRIM-19 exhibits an increase in the percentage of 
the S and G2 phase cells of the population. A previous study reports that 
GRIM-19 arrests cells at the G1 to S transition phase (Sun et al., 2010). 
Our results also support this idea since we noted that there is an increase 
in the percentage of cells progressing towards the S and G2 phase in 
GRIM-19 depleted cells. This also corroborates findings that report 
downregulation of GRIM-19 might promote cell growth in turn leading to 
development of cancers. 
4.5 STUDIES ON IFNΒ/RA TREATMENT 
4.5.1 Combination of IFNβ/RA causes more cell death than either 
drug alone 
Before embarking on studies that involve the effects of treatment 
of IFNβ/RA on mitochondrial morphology, I validated the current 
understanding about the effect of these drugs on cell health. Consistent 
with the present literature (Frey et al., 1991; Lindner et al., 1997; Marth 
et al., 1986; Moore et al., 1994), our results also prove that treatment of 
cells with either IFNβ or RA alone causes less cell death than when both of 
them are used in combination (Figure 3.12). 
4.5.2 GRIM-19 KD provides resistance to IFNβ/RA treatment 
Recollecting from the introduction, GRIM-19 was identified from a 
screening that scanned for genes that were responsible for executing cell 
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death through the IFNβ/RA pathway. This was done using an anti-sense 
technical knockout screen under the treatment of IFNβ/RA. To validate 
these results, I treated GRIM-19 KD and control KD cells with IFNβ/RA 
and assessed the percentage of cell death in each population. As expected, 
a rescue of about 20% was seen in cell death in GRIM-19 depleted cells 
(Figure 3.14). This conveys that GRIM-19 does play a role in the cell death 
pathway executed by IFNβ/RA. 
4.5.3 FNβ/RA treatment causes fragmentation of mitochondria 
After verifying the present data on IFNβ/RA treatment and its 
effects on cell death, my next aim was to observe the changes if any in the 
mitochondrial morphology when the cells are treated with the same 
combination of drugs. Upon treatment, mitochondria of HeLa cells were 
fragmented (Figure 3.13). This was much to our expectation since one of 
the first signs of cell health damage would be reflected in the 
mitochondria. Also, GRIM-19 being an important player in this pathway 
that is present in the mitochondria itself, could be implementing this 
phenomenon. There was one more observation that we could make from 
this experiment. The localization of GRIM-19 is not changed because of 
the treatment (Figure 3.13 bottom panel), suggesting that unlike 
cytochrome c, GRIM-19 does not translocate to the cytoplasm prior to 
execution of cell death. Next, I was to curious to know if GRIM-19 KD 
could rescue the mitochondrial fragmentation since it could provide 
resistance to IFNβ/RA induced cell death. We were able to detect some 
GRIM-19 KD cells with mitochondria that had close to normal morphology 
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(Figure 3.15). This leads us to propose that as a first indicator of apoptotic 
stress under IFNβ/RA, GRIM-19 disrupts the mitochondrial morphology.  
4.6 CHARACTERIZATION OF PATIENT TUMOR DERIVED GRIM-19 
MUTANTS 
After having studied the wild type protein with respect to its 
mitochondrial functions, I was interested in analyzing how certain patient 
tumour derived mutations affect the normal functioning of the protein. 
L71P, L91P and A95T were tumours detected in head and neck cancers 
from patients (Nallar et al., 2013). In this study, the authors conduct 
assays to prove that these mutations fail to inhibit STAT3 and thereby 
promote oncogenesis. T113A was identified in another study as a 
potential site for phosphorylation (Palmisano et al., 2007). I, thus, chose 
these four mutations to characterize in an effort to elucidate the 
mechanism of pathogenesis underlying the carcinomas harbouring these 
mutations. To begin with,   these were overexpressed in HeLa cells and 
the mitochondrial morphology observed. As shown in Figure 3.16, GRIM-
19 mutants did not cause alterations in the mitochondrial morphology.  
Since our previous results show that knockdown of GRIM-19 
causes an increase in ROS production, I examined the effect of mutants on 
the same. To exclusively study the effects of mutants, a GFP tagged GRIM-
19 was overexpressed in the GRIM-19 KD stable cell lines lest the effect of 
endogenous GRIM-19 could interfere. In doing this, we first had to ensure 
that the mutants could be expressed in the KD cells. I took to Western Blot 
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to prove this (Refer Figure 3.17 C). Figure 3.17 A and B show that the 
expression levels of the mutants are comparable to each other and the 
wild type protein.  
Using this as a technique to assess the effect of mutants, ROS 
production and mitochondrial potential in cells expressing the mutants 
were measured. As far as mitochondrial potential was concerned, the 
mutants did not disrupt the normal maintenance and the intensity of the 
TMRM dye was comparable across the control KD cells, GRIM-19 KD cells 
as well as the samples expressing mutants and wild type (Refer Figure 
3.18).  
All the mutants consistently showed an increase in ROS production 
which was higher than both the KD cells and wild type overexpressing 
protein (Figure 3.19). In this scenario, the mutants fail to rescue the ROS 
production indicating that this may be a factor contributing to their 
pathogenecity. This is in support with studies reporting an increase 
cellular ROS levels in various cancer tissues (Liou and Storz, 2010; 
Pelicano et al., 2004). 
4.7  CONCLUSION 
In this thesis, I have shown that GRIM-19 localizes mainly to the 
mitochondria in the cell and that at a sub-mitochondrial level, it is part of 
the inner mitochondrial membrane. Our results demonstrate that GRIM-
19 does not play a significant role in maintenance of mitochondrial 
morphology or dynamics. However, the depletion of GRIM-19 causes an 
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increase ROS production which is consistent with previous research. 
downregulation of GRIM-19 promotes oncogenesis and several cancer 
tissues exhibit an increase in cellular ROS levels. Furthermore, I show that 
IFNβ/RA treatment causes the fragmentation of mitochondria which is 
partially rescued by the knockdown of GRIM-19 indicating that upon the 
drug treatment, mitochondrial stability is lost via a GRIM-19 dependent 
mechanism. Further studies are needed to extrapolate the mechanisms 
behind the increase in ROS levels under GRIM-19 KD and the changes in 
mitochondrial morphology upon IFNβ/RA treatment.   
4.8 FUTURE WORK 
Many studies have reported that STAT3 and GRIM-19 interact with each 
other and this is in particular significant in the pathology of tumor cells 
(Lufei et al., 2003; Okamoto et al., 2010; Zhang et al., 2003; Zhou et al., 
2009). Besides, the relevance of this interaction to my current study 
stems from few key papers which report the presence of mitochondrial 
STAT3 (Gough et al., 2009; Wegrzyn et al., 2009; Zhang et al., 2013). 
However, what is lacking in these studies is the correlation and inter-
dependency of GRIM-19 and STAT3 under the investigated conditions. 
These links play a vital role in designing future experiments in order to 
formulate a mechanism for pathogenesis of tumor cells in case of an 
anomaly in GRIM-19 or STAT3 proteins. For this, a mito-targeted STAT3 
could be used. The level of STAT3 in the mitochondria in the presence and 
absence of GRIM-19 will provide an idea of the dependency of the two 
proteins on each other to be present on the mitochondria. Once this is 
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established, the effect of mito-targeted STAT3 on ROS in the presence and 
absence of GRIM-19 could be investigated. This is would help complement 
the physiological significance of the interaction of the two proteins. One 
possible theory of an increase in ROS causing cancer could be through 
activation of STAT3. To verify the same, ROS scavengers could be used in 
the background of GRIM-19 KD to ascertain the level of activated STAT3. 
Results from such experiments would form a framework of working 
model involving GRIM-19 and STAT3 in light of cancer cells. 
Another dimension to the cell death activity of GRIM-19 could be 
investigated by conducting studies on the interaction of GRIM-19 and 
GW112, a putative binding partner of GRIM-19 that impedes its pro-
apoptotic function. Knock down of GW112 should lead to a more 
profound effect of the cell death activity of GRIM-19. Also, the site of 
interaction of GRIM-19 and GW112 could be determined by truncation 
mutant studies of both proteins. Once this is established, further tests on 
the effect of the interaction on mitochondrial functions such as ROS and 
mitochondrial potential would provide an evidence of the balance 
maintained under normal conditions which otherwise go haywire. These 
would go on to widen the knowledge on the housekeeping activities of 
GRIM-19. 
Another branch of study that could be undertaken related to the current 
project is one involving the IFNβ/RA pathway. Since not many proteins 
that are part of this cascade are known, it would be useful to stimulate the 
cells with IFNβ/RA and identify other unique proteins that help in 
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execution of cell death through this pathway. For the same, after 
stimulation of cells with IFNβ/RA, an SDS-PAGE could be carried out to 
identify bands that are exclusive in lanes loaded with stimulated cells as 
against unstimulated control cells. These bands could be cut and analyzed 
through mass spectrometry to check for other potential players in this 
pathway. This could lead to further investigations on the downstream 
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